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Summary 
1 Summary 
Reactive gliosis is an early pathological feature common to most neurodegenerative 
diseases and retinal pathologies. Under physiological conditions, Müller cells, the most 
abundant glia cell type of the retina, maintain a critical retinal homeostatic balance. After 
stress or retinal injury, Müller cells become activated and perform a variety of tasks 
including recycling of neurotoxic glutamate, formation of the glia scar to inhibit lesion 
spreading, restoration of the blood supply, and inhibition of neuronal apoptosis by growth 
factor secretion and restoration of the blood-retinal barrier. However, the Müller cell 
response can also result in vascular leakage, pathologic neovascularization and reduced 
axonal regrowth, which is detrimental for neuronal survival and tissue recovery. This “Janus 
face”-like behavior of reactive glia cells has been the focus of extensive research, yet its 
impact and timely regulation remain poorly understood. 
The aim of this study was to evaluate the timing for the transition in the Müller cell gliotic 
response from neuroprotective to detrimental and the effect of an enhanced antioxidant 
activity in these cells on neuronal survival after an acute ischemia/reperfusion injury in vivo. 
Neuronal degeneration was induced by elevating the intraocular pressure above systolic 
pressure leading to retinal ischemia.  
To analyze the temporal pattern of the Müller cell gliotic response during and after 
ischemia, the glial toxin fluorocitrate was injected into the eye vitreous leading to specific 
inhibition of the Krebs cycle in Müller cells. The Müller cell metabolism was impaired at 
different time points before and after lesion onset. Transient Müller cell inhibition allowed 
the identification of three phases in the Müller cell gliotic response: first, early at the onset 
of the retinal lesion, reactive Müller cells are critical for neuronal survival. Metabolic 
inhibition during this phase is detrimental for neuron survival. Second, during the acute 
phase after lesion and reperfusion onset, Müllers cells seem not to play a critical role in 
neuronal survival, because impaired metabolism did not affect the neuronal cell death. 
Third, during the sub-chronic phase starting 12-18 hours after lesion, inhibition of the cell 
metabolism led to increased neuronal survival. This time frame comprises the transition 
from a neuroprotective to a detrimental response after an ischemic injury. Therefore, the 
gliotic response after ischemia can be divided in an early first neuroprotective phase 
followed by a transition phase and a later detrimental phase. 
One hallmark of ischemia is the increased level of oxidative stress, in particular during the 
reperfusion phase after lesion. Therefore, in the second part of the study, we evaluated the 
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effect of a selective increase of the antioxidant response of Müller cells on neuronal 
survival after ischemia. This was achieved by overexpression of the mitochondrial enzyme 
frataxin in these cells. After ischemia, the neuronal survival was significantly increased in 
frataxin overexpressing mice. This was accompanaied by an increase in the expression of 
antioxidative enzymes. This finding supports the notion that frataxin is neuroprotective by 
decreasing oxidative stress after an ischemia/reperfusion injury. Interestingly, Müller cells 
themselves did not show signs of an altered gliotic response, as indicated by unchanged 
expression levels of intermediary filaments after lesion. Frataxin expression was also 
associated with an increased expression of neurotrophic factors. Furthermore, support of 
the Müller cell function after lesion led to a reduced reactivity of retinal microglia, the main 
cell type involved in the inflammatory response after lesion.  
The two approaches used in this study show that the time-dependent modulation of the 
response of Müller cells and also their functional support leads to an increase in neuronal 
survival after injury, which is associated with a reduced glial detrimental response and 
enhanced intrinsic neuron-supportive mechanisms. 
Thus, modulation of the Müller cell response to lesion renders these cells a feasible target 
to improve both retinal homeostasis and the neuronal outcome after an acute ischemic 
lesion of the retina. Furthermore, our study supports the notion that glial cells might 
represent a critical target for the development of strategies aimed to reduce the neuronal 
cell loss caused by neurodegenerative pathologies and after lesion in the central nervous 
system.  
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2 Zusammenfassung 
Reaktive Gliose ist ein frühes pathologisches Merkmal der meisten neurodegenerativen 
Erkrankungen und Netzhautpathologien. Müllerzellen, der häufigste Glia-Zelltyp der 
Netzhaut, sind unter physiologischen Bedingungen für die Aufrechterhaltung eines 
homöostatischen Gleichgewichtes der Retina verantwortlich. Nach Stress oder 
Verletzungen an der Netzhaut werden Müllerzellen aktiviert und sind, unter anderem, für 
die Bildung der Glia-Narbe (Unterbindung der Ausweitung der Schädigung), für die 
Wiederherstellung der Blutversorgung und der Blut-Retina Schranke sowie für die 
Hemmung der neuronalen Apoptose durch die Sekretion von Wachstumsfaktoren 
verantwortlich. Die Müllerzell-Antwort kann jedoch auch zu einer erhöhten Durchlässigkeit 
von Blutgefäßen, pathologischer Neovaskularisation und einem reduziertem Nachwachsen 
der Axone führen, was für das neuronale Überleben und die Geweberegeneration 
nachteilig ist. Dieses „doppelgesichtige“ Verhalten von reaktiven Gliazellen liegt im Fokus 
umfangreicher Forschungen, doch deren Wirkung und zeitliche Regulierung sind noch nicht 
vollständig geklärt. 
Das Ziel dieser Studie war es, den Zeitpunkt für den Übergang der gliotischen Müllerzell-
Antwort von neuroprotektiv zu schädlich, und die Wirkung einer verstärkten antioxidativen 
Aktivität dieser Zellen auf das neuronale Überleben nach einer akuten ischämischen 
Reperfusions-Schädigung in vivo zu untersuchen. Die neuronale Degeneration wurde 
hierfür durch die Erhöhung des Augeninnendrucks über den systolischen Druck induziert, 
was zu einer retinalen Ischämie führte. 
Für die Untersuchung des zeitlichen Ablaufs der gliotischen Antwort von Müllerzellen 
während und nach der Ischämie wurde das Glia-Toxin Fluorocitrat in den Glaskörper des 
Auges injiziert. Dies führte zu einer spezifischen Hemmung des Krebszyklus in Müllerzellen 
und somit zu einem reduzierten Zellmetabolismus. Der Stoffwechsel der Müllerzellen 
konnte dadurch zu verschiedenen Zeitpunkten vor und nach Beginn der Ischämie 
unterbunden werden. Die transiente Hemmung der Müllerzellen ermöglichte die 
Identifizierung von drei Phasen der gliotischen Zellantwort. Frühzeitig zu Beginn der 
retinalen Läsion sind reaktive Müllerzellen entscheidend für das Überleben der Neurone. 
Eine metabolische Hemmung während dieser Phase wirkt sich nachteilig auf das Überleben 
der retinalen Ganglienzellen aus. Während des Fortschreitens der Läsion scheinen 
Müllerzellen keine kritische Rolle für das neuronale Überleben zu spielen, da ein gestörter 
Müllerzell-Metabolismus den neuronalen Zelltod nicht beeinflusst. Die Hemmung des 
Zellmetabolismus während der subchronischen Phase, beginnend 12-18 Stunden nach der 
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Läsion, führt jedoch zu einem erhöhten Überleben der Neurone. Zu diesem Zeitpunkt 
erfolgt der Übergang von einer neuroprotektiven zu einer Neuron-schädlichen Zellantwort 
nach einer ischämischen Verletzung. Daher kann die gliotische Zellantwort in drei 
Hauptphasen eingeteilt werden: eine frühe neuroprotektive Phase, gefolgt vom Übergang 
zu einer späteren schädlichen Phase. 
Ein charakteristisches Merkmal für die Folgen einer Ischämie ist die Erhöhung des 
oxidativen Stresses, die insbesondere während der Reperfusionsphase nach der Läsion 
stattfindet. Daher wurde im zweiten Teil der Studie die Wirkung einer selektiven Erhöhung 
der antioxidativen Antwort der Müllerzellen auf das neuronale Überleben nach Ischämie 
untersucht. Dies wurde durch Überexpression des mitochondrialen Enzyms Frataxin in 
Müllerzellen erreicht. Nach Ischämie war in Frataxin-überexprimierenden Mäusen das 
neuronale Überleben retinaler Ganglienzellen signifikant erhöht, das zudem mit einer 
erhöhten Expression von antioxidativen Enzymen korrelierte. Dieses Ergebnis stützt die 
Annahme, dass Frataxin neuroprotektiv wirkt indem es den oxidativen Stress nach einer 
ischämischen Reperfusionsverletzung verringert. Interessanterweise zeigten die 
Müllerzellen selbst keine Anzeichen einer veränderten gliotischen Antwort, was anhand 
eines unveränderten Expressionsverhaltens von Intermediärfilamenten nach der Läsion 
erkennbar war. Des Weiteren war die Unterstützung der Müllerzell-Funktion mit einer 
gesteigerten Expression neurotropher Faktoren assoziiert. Zusätzlich führte dies zu einer 
verminderten Reaktivität der retinalen Mikrogliazellen, dem Zelltyp, der an der 
Entzündungsreaktion nach der Läsion beteiligt ist. 
Die beiden in dieser Studie verwendeten Ansätze zur Modulation der gliotischen 
Müllerzellantwort zeigen, dass eine zeitabhängige Beeinflussung oder eine funktionelle 
Unterstützung der Müllerzellen zu einer Erhöhung des neuronalen Überlebens nach einer 
retinalen Verletzung führen. Dies geht einher mit einer verminderten Neuron-schädlichen 
Gliazell-Antwort und einer Verstärkung der intrinsischen unterstützenden Mechanismen für 
retinale Ganglienzellen. 
Die Möglichkeit der Modulation der Müllerzell-Antwort macht diese Zellen zu einem 
lukrativen Ziel zur Verbesserung der retinalen Homöostase und des neuronalen Überlebens 
nach einer akuten retinalen Ischämie. Darüber hinaus unterstützt unsere Studie die 
Annahme, dass Gliazellen ein kritisches Ziel für die Entwicklung von Strategien darstellen 
könnten, die darauf abzielen, den durch neurodegenerative Pathologien und nach Läsionen 
im Zentralnervensystem verursachten neuronalen Zellverlust zu reduzieren.  
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3 Introduction 
 The central nervous system and the retina 3.1
The central nervous system (CNS) integrates information that it receives to coordinate and 
influence the activity of all body parts of all multicellular animals. From insects to mammals, 
the CNS comprises a network of between 100.000 (fruit fly) and 1014 (human) neurons 
which mediate information transmission and processing. However, neurons are not the 
only cell type of the CNS. Neurons represent only half of all brain cells in mammals, 
although the proportion varies between different brain regions. The rest of the brain cells 
consist of glial cells (von Bartheld et al. 2016). Glial cells were firstly described by Rudolf 
Virchow (1821 – 1902), a German pathologist who named the cells “neuroglia”, from Greek 
for “nerve glue”. At that time, Virchow assumed that these cells, which are obviously not 
neurons, represented the connective tissue of the brain (Virchow 1858). More recently, 
however, two major roles have been assigned to this cell type, including neuronal support 
and tissue repair. Intense research during the past 30 years indicates that glia cells play an 
active role during development and in many central homeostatic processes. Neuroglias 
found in the CNS include astrocytes, oligodendrocytes, NG2-glia and ependymal cells. All 
these cells in the CNS are referred to either as macroglia or microglia, whereas the cells in 
the peripheral nervous system are known as Schwann cells or satellite glial cells.  
The neural retina is anatomically and developmentally an extension of the brain. It 
comprises highly specialized cell types, which generate visual information and transmitt 
them between the eye and the brain. During development, the retina and optic nerve 
extend from the diencephalon. The first retinal cells to be born are ganglion cells, which are 
the only neurons to project axons to the brain. These are followed by horizontal cells, cones 
and displaced amacrine cells. Later, amacrine cells, bipolar cells, rod cells and Müller cells 
are generated, with Müller cells being the last cells to become post-mitotic (Young 1985). 
Retinal cells form a 9-layered structure, with their cell nuclei and somas located in nuclear 
layers and the ganglion cell layer (GCL), and cellular extensions and synapses located in the 
plexiform layers and the nerve fibre layer (NFL). The sensory components of the retina are 
made of two types of photoreceptors, rods and cones. The photoreceptor outer segments 
are located in the retinal pigment epithelium (RPE), and the somas reside in the outer 
nuclear layer (ONL). Signals from photoreceptors are conveyed by interneurons comprising 
bipolar- horizontal- and amacrine cells which are found in the inner nuclear layer (INL) and 
6 
 
Introduction 
further project to retinal ganglion cells (RGCs) in the GCL. The axons of the RGCs form the 
optic nerve (ON) and transmit the visual information to the visual cortex in the brain. 
 Retinal glial cells 3.2
In the adult retina (figure 1), the glial population consists of two macroglial cell types 
(astrocytes and Müller cells) and the microglia. Müller cells form the structural scaffolding 
of the retina and span the entire retinal thickness. Astrocytes reside in the NFL and their 
processes project in the GCL/inner plexiform layer (IPL). Microglia are distributed in the 
plexiform layers, GCL and NFL (Bosco et al. 2011; Chen et al. 2002).  
 
 
Figure 1: Schematic representation of the retinal layers and cellular components of the retina including 
neuronal, glial and sensory cell types. NFL = nerve fibre layer, GCL = ganglion cell layer, IPL = inner plexiform 
layer, INL = inner nuclear layer, OPL = outer plexiform layer, ONL = outer nuclear layer, RPE = retinal pigment 
epithelium; BV = choroidal blood vessels, modified after Boia et al. (2015).  
 
Astrocytes enter the developing retina from the brain along the optic nerve together with 
blood vessels and migrate into the retina through the optic nerve head. They spread 
towards the peripheral margins of the retina but remain restricted to the GCL/NFL. 
Astrocytes have a characteristic stellar-like morphology with a flattened cell body and a 
series of fibrous radiating processes branching deeper into the retinal layers, ensheathing 
blood vessels and axons (Stone and Dreher 1987; Huxlin et al. 1992; Chan-Ling 1994; Kur et 
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al. 2012; Vecino et al. 2015). As the main producer of VEGF (vascular endothelial growth 
factor), astrocytes offer developmental support for the retinal vasculature during both 
normal (Stone et al. 1995) and pathological (Ozaki et al. 2000) vessel formation.  
Müller cells are the most abundant glial cell type in the vertebrate retina and are 
homogeneously distributed in this tissue (Wang et al., 2016). They have a bipolar 
morphology with somas residing in the INL, from which radially oriented processes emerge, 
extending from the inner limiting membrane to the outer limiting membrane. Müller cells 
extend apical microvilli into the sub-retinal space between the inner segments of 
photoreceptor cells, whereas on the opposite side, the inner processes approach the vitreal 
surface forming endfeet that border the basal lamina between the vitreous body and the 
neuroretina. In the nuclear layers, the lamellar processes of Müller cells form structures 
that envelop the cell bodies of neuronal cells where they support synaptic functions similar 
to those of brain protoplasmic astrocytes (Rasmussen 1972; Hama et al. 1978; Reichenbach 
et al. 1989; Clarke and Barres 2013; Reichenbach and Bringmann 2013; Allen 2014; Vecino 
et al. 2015). Müller cells have overlapping functions with astrocytes and are important for 
retinal cell and tissue homeostasis, including regulation of the K+ and water content, 
secretion of trophic factors, removal of metabolic waste, and neurotransmitter recycling. 
Müller cells, together with astrocytes, are essential for the organization and maintenance of 
the blood–retina barrier (BRB). Müller cells participate in the visual cycle and act as optic 
fibers guiding light through the retina (Ransom and Orkand 1996; Newman and 
Reichenbach 1996; Wang and Kefalov 2009; Wang and Kefalov 2011; Reichenbach and 
Bringmann 2013). Furthermore, similar to astrocytes in the brain, Müller cells provide 
metabolic support to surrounding retinal cells. They obtain glucose from the circulation to 
produce lactate, the primary metabolite used by retinal cells to produce ATP. Müller cells 
convert most of the glucose aerobically into lactate, instead of carbon dioxide and water, 
by oxidative phosphorylation via the so-called Warburg effect (Poitry-Yamate et al. 1995; 
Casson et al. 2012). Müller cells also accumulate glucose in internal cellular glycogen stores 
(Dringen et al. 1993; Kuwabara et al. 1961). Under metabolic stress, retinal Müller cells can 
provide metabolic support to retinal neurons by activating anaerobic glycolysis thereby 
oxidizing alternative substrates, such as lactate, glutamate or glutamine (Winkler 1981; 
Winkler et al. 2000; Winkler et al. 2003; Stone et al. 1999; Reichenbach and Bringmann 
2010; Kitano et al. 1996). In addition to metabolic support, during stress, Müller cells also 
provide neurons with antioxidants such as glutathione (Schütte and Werner 1998). 
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Microglia are resident macrophages of the retina. They are long-lived cells predominantly 
maintained via self-renewal under steady-state conditions. Microglia have a ramified 
morphology with small somas and extensive branching of the dynamic processes. They are 
involved in active surveillance of their surrounding microenvironment (Nimmerjahn et al. 
2005). Microglia in the normal and healthy tissue are maintained in a quiescent state but 
play an important role in supporting tissue and cell homeostasis. Furthermore, microglia 
constitute the first line of defense in CNS pathologies and become activated by various 
degenerative diseases and regulatory factors, thereby removing the damaged cells by 
phagocytosis (Dheen et al. 2007).  
 Reactive gliosis 3.3
Glia cells play a key role in the brain and in the retinal response to injury. They react to 
homeostatic changes by altering their morphology and function. Glia cells are able to 
withstand most insults, in contrast to the extremely vulnerable neurons (Anderson and 
Davis 1975; Schmuck et al. 2002; Winkler et al. 2000). Thus, glia cells take part in 
pathogenic processes and critically influence the neuronal fate. Müller cells, as well as 
astrocytes in the brain, show a “Janus face” like behavior after lesion. Gliotic alterations of 
Müller cells protect neuronal cells and retinal tissue, but also contribute to neuronal 
degeneration and edema development in the diseased retina (Bringmann et al. 2006; 
Bringmann et al. 2004). For instance, neuroprotective growth factors including glial cell line-
derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), brain-derived 
neurotrophic factor (BDNF), and nerve growth factor (NGF), are either released by Müller 
cells or exert their effects indirectly by activating Müller cells (Rhee et al. 2013; Kirsch et al. 
1997; Hauck et al. 2006; Wahlin et al. 2000; Wang et al. 2011). However, Müller cells also 
release VEGF which can be both neuroprotective by means of restoring blood supply and 
inhibiting apoptosis at early stages of reperfusion, and detrimental by inducing leakage and 
neovascularization in chronic diseases (Croll et al. 2004; Yasuhara et al. 2004; Kilic et al. 
2006; Pierce et al. 1995; Tolentino et al. 2002). Glial scar formation by activated glial cells 
protects unlesioned neighboring tissue by restoring the blood-brain barrier (BBB) and the 
BRB integrity, restricting the inflammatory response and, thereby, limiting cellular 
degeneration (Faulkner et al. 2004). However, the glial scar also prevents neuronal recovery 
and impedes repair and remodeling of the neuronal tissue. Reactive glia secrete a number 
of extracellular matrix substrates known to inhibit dendritic and axonal growth (Shen et al. 
2008; Moreau-Fauvarque et al. 2003). Moreover, Müller cells mediate cytotoxicity by 
releasing soluble factors such as the proinflammatory cytokine TNF-α (tumor necrosis 
9 
 
Introduction 
factor-alpha) which activates TNF-R1 (tumor necrosis factor-receptor 1) and triggers 
apoptosis (Cotinet et al. 1997; Tezel et al. 2001).  
Beside Müller cells and astrocytes, microglia are also involved in the retinal gliotic response 
to lesion. After injury, microglia become activated, change their morphology from ramified 
to amoeboid and accumulate at the lesion site. Microglia proliferate and secrete 
chemokines and cytokines to attract other immune cells or induce cell proliferation. They 
are involved in recognition and elimination of apoptotic neurons by phagocytosis or by 
presentation of antigens to infiltrating T-cells and augmentation of the immune response. 
On the other hand, they can also down-regulate T-cell responses or trigger a vicious cycle of 
persistent activation and recruitment of additional inflammatory cells (Dheen et al. 2007; Li 
et al. 2015).  
Active cross-talk between microglia and Müller cells, mediated by several neurotrophic 
factors, can directly influence the release of GDNF, leukemia inhibitory factor (LIF), CNTF 
and basic fibroblast growth factor (bFGF) by Müller cells (Harada et al. 2002; Wang et al. 
2011). On the other hand, activated Müller cells secrete diazepam binding inhibitor (DBI), a 
ligand for the translocator protein 18 kDa (TSPO), which is expressed in activated microglial 
cells and limits microglial reactivity during development (Karlstetter et al. 2014). The same 
mechanism applies to Müller cell gliosis during retinal degeneration, when DBI release 
provides an inhibitory signal to excessive microglial activation (Wang et al. 2014). 
Suppression of microglial immune response has been shown to decrease RGC death and 
increase axon regeneration in several studies (Heiduschka and Thanos 2006; Sun et al. 
2013; Cukras et al. 2012; Levkovitch-Verbin et al. 2014).  
 Reactive gliosis as a therapeutic target 3.4
Glial neuroprotective and detrimental responses after lesion have been the focus of 
extensive research, however, the underlying mechanisms and the timing of these responses 
are not fully understood (Bringmann et al. 2009; Johnson and Morrison 2009; Vázquez-
Chona et al. 2011). Recently, three phases discriminated by gene expression patterns have 
been described for the gliotic response of macroglia cells after ischemia/reperfusion 
injuries. In the first phase at reperfusion onset, differentially expressed genes are related to 
changes in metabolism. In contrast, in the second phase, 24 hours after lesion, enhanced 
inflammatory and immune responses as well as cell death-related genes become highly 
regulated. This period is a critical target for the development of interventional therapeutic 
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approaches. Activation of the complement system pathway characterizes the later stages of 
the gliotic response (Andreeva et al. 2014).  
The precise timing of the transition between macroglial supportive and detrimental 
responses to lesion, and the underlying mechanisms, are poorly understood. The critical 
role of the glial network in regulating neuronal homeostasis, but also as a detrimental 
factor after injury or in disease, converts it to a potential therapeutic target for the 
treatment of neurodegenerative diseases. In order to develop feasible therapeutic 
approaches, it is critical to determine the mechanisms involved in glial cell activation during 
injury, including the time course of reactive gliosis and putative detrimental mechanisms.  
 Aims of the study 3.5
The aims of this study were: 1) to determine the timing of the switch in the Müller cell 
gliotic response from neuroprotective to detrimental, and 2) to evaluate the effect of an 
enhanced antioxidative activity in Müller cells on neuronal survival after an acute 
ischemia/reperfusion injury in vivo. 
In this study the following hypotheses were tested: 
1. Activation of neuroprotective and detrimental gliotic responses in Müller cells after 
an acute ischemic insult follows a time-dependent pattern.  
2. Transient metabolic inhibition of Müller cells during or early after an ischemic 
lesion leads to increased neuronal degeneration. 
3. Transient sub-chronic inhibition of Müller cells leads to increased survival of retinal 
ganglion cells. 
4. Improved neuroprotection after transient inhibition of Müller cell activity is 
associated with reduced oxidative stress and increased neuronal support.  
5. Support of the glial redox homeostasis by overexpression of the mitochondrial 
enzyme frataxin leads to enhanced neuronal survival. 
For this study, an established model of acute glaucoma caused by elevated intraocular 
pressure (IOP) above systolic pressure was used to induce neuronal degeneration. 
Increased IOP leading to retinal ischemia is a major risk-factor for open-angle glaucoma 
(Coleman and Miglior 2008). Hallmarks of the ischemic lesion include energy failure, 
increased calcium influx followed by neuronal depolarization, excitotoxicity, increased 
oxidative stress, and withdrawal of neurotrophic factors. Re-oxygenation of the tissue after 
ischemia promotes neuronal degeneration by the additional production of reactive oxygen 
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species (ROS), which further potentiate inflammatory responses. Inflammation, which can 
support tissue repair mechanisms, but can also lead to chronic detrimental effects, further 
triggers ROS production and tissue damage. This cascade finally results in the death of 
neurons, glial and endothelial cells.  
In the first part of the study, the temporal pattern of the Müller cell gliotic response during 
and after an ischemic injury was analyzed. For this, the specific glial toxin fluorocitrate (FC) 
was injected into the eye vitreous at different time points before and after lesion onset in 
order to transiently inhibit the Müller cell metabolism and activity. FC has already been 
used to transiently impair glial cell metabolism in the brain (Paulsen et al. 1987) and rat 
retina (Zeevalk and Nicklas 1997). FC impairs glial activity by inhibiting the mitochondrial 
enzyme aconitase (Cheng et al. 1972). Aconitase is a key enzyme of the citric acid cycle 
(Krebs cycle). FC binds to the aconitase and blocks its activity, thereby, disrupting the Krebs 
cycle, mainly in glial cells.  
In the second part of the study, the effect of frataxin (FXN) overexpression in Müller cells on 
neuronal survival after an ischemic injury was evaluated. The mitochondrial enzyme FXN is 
upregulated in several tumor cell lines in response to hypoxic stress (Guccini et al. 2011) 
and is part of the intrinsic retinal response to ischemia (Schultz et al. 2016). FXN is involved 
in iron homeostasis and biogenesis of iron–sulfur clusters, which are part of the active sites 
of complexes I and II of the mitochondrial electron transport chain and of the enzyme 
aconitase (Bulteau 2004; Sutak et al. 2008). FXN deficiency in mice leads to changes in 
metabolism by insufficient assembly of iron-sulfur clusters and increased production of 
harmful free radicals through the Fenton reaction (Al-Mahdawi et al. 2006). In contrast, 
elevated FXN levels reduce the effects of oxidative stress and increase cell survival after 
oxidative stress-induced cell death (Shoichet et al. 2002; Runko et al. 2008). To evaluate the 
effects of increased FXN expression, two mice models overexpressing FXN were generated: 
one expressing FXN ubiquitously in the retina and one specifically in retinal Müller cells.  
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4 Summary of the manuscripts 
 
Increased frataxin levels protect retinal ganglion cells after acute ischemia/reperfusion in 
the mouse retina in vivo, Rowena Schultz, Otto W. Witte, Christian Schmeer, published in 
the journal Investigative Ophthalmology and Visual Science, 2016, volume 57(10), 
pp.4115–4124. 
In this part of the study, it was shown for the first time that the endogenous expression of 
the mitochondrial enzyme frataxin is upregulated at mRNA and protein levels in response 
to a transient retinal ischemia in vivo. Furthermore, ubiquitous frataxin overexpression 
significantly increased neuronal survival after lesion. This was associated with an up-
regulation of antioxidant enzymes further indicating that frataxin induces neuroprotection 
by decreasing oxidative stress. 
My contribution to this study consisted of the planning and independent realization of the 
experimental work, including mRNA and protein analysis via qPCR and Western blot, 
microscopic image acquisition, analysis and graphical presentation, data gathering and 
statistical evaluations, as well as partial preparation of the manuscript. This amounts to 
80% of the work. 
 
Transient inhibition of Müller cells by fluorocitrate increases neuronal survival after acute 
retinal ischemia in vivo, Rowena Schultz, Twinkle Vohra, Julia Lindner, Otto W. Witte, 
Christian Schmeer, under review at the Journal of Neurochemistry (submitted on 
September 29, 2017). 
For this part of the study, Müller cell metabolism was transiently impaired using the 
gliotoxin fluorocitrate to evaluate the time-dependent activation of the Müller cell gliotic 
response after acute ischemia/reperfusion injury. Inhibition of the metabolism of Müller 
cells in the acute phase after ischemia but not before or at lesion onset increased neuronal 
survival. Furthermore, the expression of antioxidant enzymes and growth factors was 
increased after diminished Müller cell metabolism, which supports the notion that the 
gliotic response of Müller cells seem to turn detrimental at later time points after acute 
ischemia. Therefore, glia cells provide a feasible target to improve neuronal survival after 
an ischemic injury. 
My contribution to this study consisted of the planning and independent realization of the 
experimental work, in particular the biochemical assays and microscopic image acquisition. 
This was done in collaboration with the master student Twinkle Vohra. Cell culture 
experiments were established and performed in collaboration with the master student Julia 
Linder. In addition, I performed all mRNA analyses via qPCR, data gathering and statistical 
evaluations, and graphical presentation as well as preparation and revision of the 
manuscript. This amounts to 70% of the work. 
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Summary of the manuscripts 
Frataxin overexpression in Müller cells protects retinal ganglion cells in a mouse model of 
acute glaucoma in vivo, Rowena Schultz, Melanie Krug, Michel Precht, Stefanie G. Wohl, 
Otto W. Witte, Christian Schmeer, has been submitted to Scientific Reports on November 
17, 2017.  
For this part of the study, frataxin was specifically overexpressed in Müller cells to answer 
the question whether specific modulation of Müller cells would improve neuroprotection 
after an acute ischemic injury. Elevated frataxin in Müller cells resulted in increased RGC 
survival after acute retinal ischemia/reperfusion and altered expression of antioxidant 
enzymes and growth factors. These findings further support the notion that the targeted 
modulation of glial cells and their gliotic response is a putative approach to improve 
neuronal survival after injury in the central nervous system. 
My own contribution to this study consisted of the planning and independent realization of 
all experimental work, establishment of the mRNA and protein analysis via qPCR and 
Western blot, microscopic image acquisition and graphical presentation, data gathering and 
statistical evaluations, as well as preparation and revision of the manuscript. This amounts 
to 80% of the work. 
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Abstract 
Müller cells are the main glial cell type in the vertebrate retina. After injury, the reactive 
Müller cells can be neuroprotective or detrimental to neuronal survival. The time point at 
which the switch from a neuroprotective effect to a detrimental effect occurs has not been 
properly determined. Furthermore, the impact of transient functional inhibition of Müller 
cells on the detrimental effects of reactive gliosis after an ischemic lesion has not been 
investigated. 
Therefore, in this study, we evaluated the time-dependent effects of transient Müller cell 
inhibition on neuronal survival after acute ischemia/reperfusion in the murine eye. Retinal 
ganglion cell (RGC) death was induced by elevating the intraocular pressure above systolic 
pressure. Müller cell metabolism was blocked by intravitreal delivery of the gliotoxin 
fluorocitrate during lesion onset and in the reperfusion phase. RGC survival was analyzed 
seven days post lesion onset, and the mRNA expression levels of markers for gliosis and 
retinal homeostasis were evaluated 12, 24 and 48 hours after the ischemic event.  
Transient Müller cell inhibition during ischemia did not influence RGC survival; however, 
metabolic blocking after the onset of reperfusion significantly increased RGC survival. This 
was associated with decreased expression of gliosis markers and increased levels of 
antioxidant enzymes, neurotrophic factors and microglial reactivity markers. Thus, the 
inhibition of Müller cell metabolism after retinal ischemia induction blocked the 
detrimental effects of reactive gliosis. Our study indicates that selective regulation of 
Müller cell activity is a feasible approach to diminishing neuronal damage after 
development of an ischemic lesion. 
Introduction 
Retinal ischemia is a clinical condition caused by insufficient blood supply to the retina and 
is a major cause of blindness worldwide. It is associated with various disorders such as 
diabetic retinopathy, glaucoma, optic neuropathies, stroke, and other retinopathies. The 
pathological mechanisms of retinal ischemia are still not fully understood, and treatments 
for this disorder have limited effectiveness (Minhas et al. 2012). At the cellular level, 
ischemic retinal injury consists of a self-reinforcing degenerative cascade involving neuronal 
depolarization, calcium influx and oxidative stress initiated by energy failure and 
glutamatergic stimulation (Casson et al. 2004). Another pathological mechanism involves 
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withdrawal of trophic factors and this mechanism has also been suggested to play an 
important role in the pathogenesis of glaucoma (Almasieh et al. 2012).  
Müller cell and microglial activation (reactive gliosis) is an early response that is common to 
virtually every pathological alteration in the retina (Langmann 2007; Bringmann et al. 
2006). Müller cells are the most abundant glial cell population in the retina and are in 
contact with all of the other cell types. After lesioning, they protect neurons via the release 
of neurotrophic factors and free radical scavengers, the uptake of glutamate, and the 
facilitation of neovascularization (Bringmann et al. 2006). However, gliotic alterations of 
both Müller cells and microglia also lead to the formation of glial scars and the induction of 
chronic inflammation, which may contribute to neuronal degeneration and edema 
development in the diseased retina (Bringmann et al. 2006; Bringmann et al. 2004; 
Bringmann et al. 2009; Karlstetter et al. 2010). Mechanisms involved in the neuroprotective 
and detrimental responses of Müller cells, as well as their temporal activation pattern 
following lesion development, are incompletely understood (Johnson and Morrison 2009; 
Bringmann et al. 2009). This dual effect of Müller cell activation is highly relevant to the 
development of effective therapeutic approaches aimed at reducing the detrimental gliotic 
effects and improving neuroprotection. Most experimental therapies to reduce ischemic 
damage are based on prophylactic rather than therapeutic interventions, limiting their 
clinical relevance. The available evidence indicates that focusing on single targets and 
mechanisms to induce neuroprotection after ischemia does not work since multiple 
pathways in diverse cell types are involved (Bringmann et al. 2009; Vecino et al. 2015).  
The aim of this study was to evaluate the temporal pattern of Müller cell activation and the 
effect of transient inhibition of Müller cell metabolism on murine retinal ganglion cell 
survival after acute ischemia/reperfusion in vivo. Retinal ischemia was induced by acute 
elevation of the intraocular pressure (IOP) above systolic pressure (Krempler et al. 2011; 
Schultz et al. 2016). Transient Müller cell inhibition was induced by intraocular delivery of 
the gliotoxin fluorocitrate (FC), which is a specific inhibitor of glial metabolism (Virgili et al. 
1991; Zeevalk and Nicklas 1997). Changes in the expression levels of markers for gliosis, 
antioxidant enzymes, microglial reactivity, and neurotrophic factors were assessed by qRT-
PCR analysis after Müller cell inhibition. 
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Material and Methods 
Materials 
D,L-fluorocitric acid barium salt and the Cell proliferation Kit I (MTT) were obtained from 
Sigma-Aldrich (Munich, Germany). The glutamine assay kit was ordered from Abnova 
(Taipei City, Taiwan). Oxybuprocaine hydrochloride (4 g/mL) and Ofloxacin are from Bausch 
& Lomb GmbH (Feldkirchen, Germany). The reagents for the Bradford assay were 
purchased from BioRad (Munich, Germany). Chloral hydrate was obtained at Fluka (Seelze, 
Germany). For qPCR analysis the following kits were used: RNeasy micro kit (Qiagen, Hilden, 
Germany), Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, Schwerte, 
Germany), Brilliant II SYBR Green QPCR MasterMix (Agilent Technologies, Santa Clara, CA, 
USA). All other chemicals used are from Merck Millipore (Darmstadt, Germany), unless 
stated otherwise. The following antibodies were used: goat anti-BRN3a (1:300, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA, RRID:AB_2167511) and donkey anti-goat (Alexa Fluor-
488 conjugated, Molecular Probes, Leiden, The Netherlands, RRID:AB_142672). 
Animal guidelines 
Female C57BL6/J mice each weighing 18 to 20 g (12 weeks old), were used. Animals were 
bred and held at the research facility. All experiments were performed in accordance with 
the European Convention for Animal Care and with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and were also approved by the local animal 
care committee (reference numbers: 02-047/08 and 02-013/11). Animals were housed in 
standard cages in groups of 5 animals on a 14-hour light/10-hour dark cycle, with food and 
water available ad libitum, temperature ranging from 22°C to 25°C and the humidity 
ranging from 55% to 60%. 
Fluorocitrate preparation and treatment 
For each experiment, FC was freshly prepared according to Paulsen et al., (1987). Briefly, 
2.63 mg of D,L-fluorocitric acid barium salt was dissolved in 328.7 µl of 0.1 M HCl. Ba2+ was 
precipitated by adding 13.15 µl of 0.1 M Na2SO4. After adding 328.2 µl of 0.2 M Na2HPO4, 
the solution was centrifuged at 1000 x g for 5 minutes, and the pellet was discarded. The 
supernatant was adjusted to pH 7.4 by adding 6-8 µl of 1 M NaOH and then adjusted with 
0.9% NaCl to a final volume of 1 ml (final concentration 3.2 mM). 
For in vivo studies, FC was delivered via intraocular injection according to standard 
protocols (Pearce et al. 2015; Stewart 2015). Briefly, 0.5 µl saline (0.9% NaCl, vehicle 
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solution) or 0.5 μl of 3.2 mM FC (final concentration in the eye 0.32 mM) was injected into 
the vitreous chamber using a 34G microsyringe (5 µl, Hamilton Robotics, Bonaduz, GR, 
Switzerland). Animals were anesthetized with a gas mixture of 1.5% isoflurane, 40% N2O 
and 20% O2. For each eye, local anesthesia with Oxybuprocaine hydrochloride was topically 
applied before injection. The needle was inserted at an angle through the sclera (to avoid 
damage to the lens) with the tip aimed towards the vitreous body such that the substance 
was uniformly distributed. The needle was kept in the eye for 30 seconds to prevent reflux 
and then slowly withdrawn. The contralateral eye was injected with an equal volume of 
saline (0.9% NaCl) and served as a control. To avoid infections, eyes were topically treated 
with one drop of the antibiotic Ofloxacin before and after injection. A preliminary 
experiment showed reduced retinal ganglion cell (RGC) survival after repeated daily 
injections of FC. Therefore, a single injection was used in this study.  
MTT assay to assess Müller cell metabolic activity and viability 
An initial series of experiments was performed to determine the optimal FC concentration 
for Müller cell inhibition. For this, murine primary Müller cells of C57BL/6 pups, aged 8-10 
days, were cultured following the protocol from Da Silva et al., (2008). Cells were incubated 
with FC at concentrations ranging from 0.16 to 0.64 mM. After incubation for 4, 6, 12 and 
24 hours, cell viability and metabolic activity were assessed using the Cell Proliferation Kit I 
(MTT). Briefly, 5000 cells per well were seeded in a 96-well microplate. The cells were 
incubated overnight to allow them to attach. The cells were then further incubated with 10 
µl FC solution or 0.9% NaCl (vehicle). After incubation, 10 μl of the MTT labeling reagent 
(3,[4, 5 dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide, final concentration 0.5 
mg/ml) was added, and the cells were incubated for four hours. All incubation steps were 
performed at 37°C and 10% CO2. To determine the cell viability, the MTT reaction was 
stopped by adding 100 µl of solubilization solution (10% SDS in 0.01 M HCl), and the 
absorbance was measured after complete solubilization of the released formazan crystals in 
a microplate reader at 550 nm, corrected against 650 nm.  
Aconitase activity assay 
Retinal aconitase activity after FC treatment was assessed according to the protocol from 
Gardner et al. (1994). Animals were treated with a final concentration of 0.32 mM FC and 
sacrificed four hours later. Retinae were removed and shock frozen. Whole retinal tissue 
was homogenized in buffer containing 50 mM Tris-Cl (pH 7.4) and 0.6 mM MnCl2 by brief 
ultrasonication (Sonoplus, Bandelin, Germany) for 5 sec and clarified by centrifugation at 10 
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000 x g for 5 min. Triplicates of the homogenates, consisting of a 200-µl reaction mixture 
containing 50 mM Tris-HCl (pH 7.4), 5 mM sodium citrate, 0.6 mM MnCl2, 0.2 mM NADP+, 
1-2 units of isocitrate dehydrogenase, and 20 µg of extracted proteins were assayed for 
aconitase activity by measuring the rate of formation of Nicotinamide adenine dinucleotide 
phosphate hydrate (NADPH) from NADP+. The rate of formation was monitored by the 
linear increase in absorbance at 340 nm at 25°C. An initial lag in NADPH formation is seen in 
assays of low aconitase activity, which presumably reflects the delayed accumulation of cis-
aconitate (Krebs and Holzach 1952). Thus, the linear rates starting after 40 minutes of the 
90-min assay were used to determine the activity. The increase in absorbance was plotted 
against the time, and differences in treatment groups were confirmed by covariance 
analysis.  
Determination of glutamine levels 
The intraretinal glutamine concentration was detected using a glutamine assay kit (Abnova, 
Taipei City, Taiwan), which provides a quantitative colorimetric determination of glutamine 
at 565 nm with a detection range of 0.023 to 2 mM. Animals treated with FC were sacrificed 
by an overdose with 30% chloral hydrate at 3, 4, 6, 12 and 24 hours after treatment. 
Retinae were kept in PBS and homogenized by means of ultrasonication (Sonoplus) at 
minimum power for 5 sec. After centrifugation at 10 000 x g for 10 min at 4°C, the protein 
concentration of the supernatant was determined using the Bradford assay. The glutamine 
concentration was measured as indicated in the protocol provided with the kit. The 
glutamine concentration obtained was corrected for glutamate and for total retinal protein. 
The results are given as a percentage of control levels.  
Induction of transient retinal ischemia 
Transient retinal ischemia (TRI) was induced as described previously (Krempler et al. 2011; 
Schultz et al. 2016). Briefly, mice were anesthetized with an intraperitoneal injection of 5% 
chloral hydrate in phosphate-buffered saline (PBS; 500 mg/kg body weight; Fluka, Seelze, 
Germany). Chloral hydrate was used to avoid side effects to the central nervous system. 
One eye was locally anesthetized with Oxybuprocaine hydrochloride followed by 
cannulation of the anterior chamber with a 30-gauge needle connected to a reservoir 
containing normal saline. To induce retinal ischemia, the intraocular pressure was increased 
above systolic pressure by raising the saline reservoir for 45 minutes. Increased pressure 
was verified by means of an Induction/Impact Tonometer (TonoLab; Tiolat Ltd., Helsinki, 
Finland). Then, the cannula was removed, and blood was allowed to naturally re-perfuse 
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the retinal tissue. Body temperature was maintained on a digitally controlled heating pad 
for the duration of the procedure and recovery. Animals were monitored on a daily base by 
the experimenter. Mice with signs of cataract were excluded from the study. The animals 
for FC treatment before or after ischemia were assigned at random by the principal 
investigator and mixed with non-injected animals. 
Immunofluorescent staining 
Animals were sacrificed with an overdose of chloral hydrate (30%) seven days after TRI. 
Eyes were enucleated and retinae flattened by making incisions from the periphery halfway 
to the optic nerve to form four symmetric lobes. Whole mounts were then fixed in 4% PFA 
for 20 min and permeabilized with 0.3% Triton X-100 in PBS for 45 min at RT. Blocking was 
achieved by incubation with a solution consisting of 3% bovine serum albumin and 10% 
normal donkey serum in PBS supplemented with 0.3% Triton X-100 for 2 hours at RT. After 
non-specific binding was blocked, whole mounts were incubated with a primary antibody 
raised against the RGC-specific transcription factor Brn3a (goat anti-Brn3a, 1:300; Santa 
Cruz) in 5% normal donkey serum overnight at 4°C. After washing with PBS, retinae were 
incubated with the corresponding secondary antibodies (Molecular Probes, Leiden, The 
Netherlands) in 10% normal donkey serum for one hour at RT. Specificity of the staining 
was tested by incubation without the primary antibody. 
Retinal ganglion cell quantification 
RGC survival was evaluated on retinal whole mounts seven days post ischemia. Brn3a-
labeled RGCs were acquired with a laser scanning microscope (LSM 710, Zeiss, Jena, 
Germany) and counted in tile scans close to the optic nerve in each of the four whole-
mount lobes (0.54 mm2 each, 4 fields in total). Cell density was automatically determined 
after image processing performed with ImageJ (U.S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij; version 1.46), following a protocol developed by 
Salinas-Navarro et al., (2009) with some modifications. Briefly, z-stacking was performed to 
cover the entire thickness of the ganglion cell layer. Maximum-intensity-projected images 
were used for quantification. After subtracting the background, images were converted to 
8-bit images, and brightness and contrast were adjusted to better visualize cells without 
increasing the background. Images were thresholded, and closely packed nuclei were 
separated with the Watershed function. The “Analyze Particles function” was then used 
with a minimum size of 30 μm to count cells. Parameters for cell-counting were calibrated 
by comparison with a subset of manually counted images.  
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The number of surviving RGCs was expressed as the number of cells per square millimeter, 
and final cell counts are given as the percentage of the corresponding contralateral and 
unlesioned eyes. The image acquisition and analysis was performed blinded. The whole 
mount preparations of animals treated with FC, non-injected ischemic controls and naïve 
mice were mixed randomly and coded by the principal investigator. 
Quantitative polymerase chain reaction (qRT-PCR) analysis 
Animals were killed with an overdose of chloral hydrate (30%) 12, 24, and 48 hours after 
TRI lesion. Eyes were enucleated, and retinae were shock frozen in liquid nitrogen. Isolation 
of mRNA was carried out using the RNeasy micro kit, and equal amounts of total retinal 
mRNA were reverse transcribed into cDNA using a Revert Aid First Strand cDNA Synthesis 
Kit. Quantitative RT-PCR was used to measure expression levels of the following markers: 1) 
the gliosis markers glial fibrillary acidic protein (Gfap), vimentin (Vim), glutamate aspartate 
transporter (Glast) and glutamine synthetase (Glul); 2) the inflammatory markers tumor 
necrosis factor alpha (Tnf-α), interleukin 1 beta (Il-1β) and cluster of differentiation 68 
(Cd68); 3) the antioxidant enzymes superoxide dismutase 1 and 2 (Sod1 and Sod2), catalase 
(Cat), glutathione peroxidase 1 (Gpx1) and heme oxygenase-1 (Hmox1), and 4) the 
neurotrophic factors brain-derived neurotrophic factor (Bdnf), glial cell line-derived 
neurotrophic factor (Gdnf), nerve growth factor (Ngf) and ciliary neurotrophic factor (Cntf). 
The PCR was carried out with Brilliant II SYBR Green QPCR MasterMix using the primer 
sequences depicted in table 1. After denaturing at 95°C for 10 minutes, 40 amplification 
cycles were carried out as follows: denaturation at 95°C for 60 sec, annealing at 60°C for 30 
sec, and elongation at 72°C for 30 sec. The housekeeping genes glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) and hypoxanthine–guanine phosphoribosyltransferase 
(Hprt) were used as reference genes. To determine the relative expression ratio (fold 
change) of the target genes, the analysis introduced by Pfaffl (2001) was applied. Analysis 
was repeated twice. 
Statistical Analysis 
All results are expressed as the mean ± standard error of the mean (SEM). Each group 
consisted of at least four animals. Outliers were determined using the Dixon's Q test. For 
cell culture experiments, the efficacy of different dosages of FC via MTT-Assay was analyzed 
using one way ANOVA followed by a Holm-Sidak post hoc test. Statistical significance for 
the aconitase activity was determined using the one-way ANCOVA test. Differences in 
glutamine level were analyzed using One-way ANOVA followed by Holm-Sidak post hoc 
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analysis. For RGC survival analysis statistical significance was assessed by using One-way 
ANOVA followed by Holm-Sidak post hoc analysis for comparing control mice and 
treatment groups. For relative gene expression ratios, One-way ANOVA followed by Holm-
Sidak post hoc analysis was used for the time-dependent expression levels and Two-way 
ANOVA followed by Holm-Sidak post hoc analysis was applied for comparison of lesion 
effects 24 and 48 hours after ischemia. SigmaPlot (13.0v) was used and the level of 
significance and was accepted at p<0.05.  
 
Results 
Fluorocitrate selectively inhibited Müller cell metabolism 
We first determined the effect of FC on Müller cell metabolism in the mouse retina. FC 
decreased the metabolic activity of cultured primary Müller cells in a dose dependent 
manner as determined by the MTT assay. Inhibition was already achieved four hours after 
adding FC to the culture medium. Metabolic activity was reduced by 20% and 23% after the 
addition of 0.32 and 0.64 mM FC, respectively (absorbance for 0.32 mM FC = 0.091 ± 0.004 
and for 0.64 mM FC = 0.088 ± 0.003 vs. 0.114 ± 0.003 in saline-treated cells, P<0.05, figure 
2A). A lower concentration of FC (0.16 mM) inhibited cell metabolism only after 12 hours of 
incubation. Inhibition by 0.64 mM FC was long-lasting, lasting up to 24 hours. To achieve a 
quick and short Müller cell inactivation, an FC concentration of 0.32 mM was chosen for all 
in vivo experiments. This concentration has been used in previous studies with the rat 
retina (Virgili et al. 1991). 
Since FC directly inhibits the activity of the enzyme aconitase, which forms part of the Krebs 
cycle, we determined the activity of this enzyme after intraocular delivery of 0.32 mM FC. 
Aconitase activity in treated eyes was significantly lower than in untreated control eyes 
(figure 2B). Additionally, glutamine levels were significantly lower between three and six 
hours in FC-treated eyes than in untreated control eyes (39 ± 13% vs. 100 ± 23% in 
untreated eyes, P<0.05, figure 2C).  
Fluorocitrate increased retinal ganglion cell survival after acute retinal 
ischemia/reperfusion 
Next, we evaluated the effect of transient Müller cell inhibition before introducing an 
ischemic lesion and during the early and late reperfusion phases on RGC survival after 
lesioning (figure 1 and figure 3A/B). 
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Acute ischemia led to a high loss of RGCs seven days after lesion onset (36 ± 2% vs. 97 ± 3% 
in control retinae, P<0.001). FC delivery four hours before lesion onset had no significant 
effect on RGC survival (28 ± 1% vs. 37 ± 1% in untreated ischemic retinae, n.s.). FC delivery 
at the onset or after six hours of reperfusion also had no effect on RGC survival (reperfusion 
onset: 35 ± 5% vs. 37 ± 1%, n.s.; six hours reperfusion: 38 ± 3% vs. 37 ± 1%, n.s.). However, 
FC delivery 12 hours after lesion led to a significant increase in RGC survival seven days 
after lesion (66 ± 6% vs. 37 ± 1%, P<0.001).  
Expression levels of markers for cellular stress response mechanisms were altered after 
transient Müller cell inhibition 
To determine the mechanisms involved in neuroprotection after inhibition of Müller cell 
metabolism, we measured the mRNA expression levels of markers for gliosis, inflammation, 
antioxidant enzymes and neurotrophic factors. Detailed results are summarized in table 2. 
Expression levels of gliosis markers were altered after ischemia and FC delivery 
Both Gfap and Vim mRNA expression levels were significantly higher than the naïve control 
levels. The Gfap levels were highest at 48 hours after lesion onset (P<0.001, figure 4A). Vim 
levels were increased after lesion onset, starting at 12 hours (P<0.001, figure 4A). Glast 
levels first decreased at 12 hours after lesion onset but were upregulated again at 48 hours 
(P<0.05 and P<0.001, respectively, figure 4A) compared to naïve control levels, whereas 
glutamine synthetase (Glul) was consistently downregulated starting at 12 hours (P<0.001, 
figure 4A). 
FC delivery 12 hours after lesion onset had a strong effect on the expression of these 
markers. The Gfap levels 24 and 48 hours after lesion onset were lower than the Gfap levels 
in the untreated ischemic eyes (P<0.001, figure 4B). Vim expression was further increased 
48 hours after lesion onset and FC injection (P<0.001, figure 4C). FC injection reduced the 
ischemia-mediated increase in Glast expression 24 and 48 hours after lesion onset 
(P<0.001, figure 4D). The reduction in Glul was less pronounced 24 hours after lesion onset 
(P<0.05) but reached the same level as that without FC treatment at 48 hours (figure 4E).  
Ischemia and FC led to increased expression of inflammation-associated genes  
Tnf-α expression rapidly increased and was highest after 12 hours of reperfusion (P<0.001, 
figure 5A); expression then slightly decreased up to 48 hours after lesion onset (P<0.05, 
figure 5A). A similar expression pattern was observed for Il-1β, with an initial strong 
increase at 12 hours after lesion onset (P<0.05, figure 5A) and a slightly reduction at 48 
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hours of reperfusion (P<0.05, figure 5A). Cd68 expression also increased after lesion onset, 
starting at 12 hours (P<0.001, figure 5A) and was highest at 48 hours of reperfusion 
(P<0.05, figure 5A). 
Tnf-α expression was further increased after FC delivery and remained elevated between 
24 and 48 hours of reperfusion compared with the levels in untreated mice (P<0.05, figure 
5B). The expression of Il-1β did not change after ischemia induction and FC injection (figure 
5C); however, Cd68 levels were increased at 24 and 48 hours after lesion onset in FC-
injected mice compared with the levels in untreated mice (P<0.05, figure 5D). 
Expression of antioxidant enzymes increased after FC treatment 
Sod1 expression was highest at 24 hours of reperfusion and remained high 48 hours after 
lesion onset (P<0.001, figure 6A). Sod2 expression was highest at 12 hours of reperfusion 
(P<0.001, figure 6A) but returned to the control level at 48 hours (figure 6A). The 
expression of Cat was decreased 12 hours after lesion onset (P<0.05) and then showed a 
continuous increase over control levels up to 48 hours after lesion onset (P<0.001, figure 
6A). Gpx1 expression peaked at 24 hours of reperfusion (P<0.001, figure 6A) and remained 
elevated until 48 hours of reperfusion. The elevation of Hmox1 expression was highest at 
12 hours of reperfusion (P<0.001) and remained above the control levels until 48 hours of 
reperfusion (P<0.001, figure 6A). 
FC delivery starting 12 hours after reperfusion onset had a strong effect on the expression 
of these markers. The expression of both Sod1 and Sod2 was significantly increased by FC 
24 and 48 hours after lesion onset compared with the levels in ischemic untreated eyes 
(P<0.001, figure 6B/C). FC blocked the increase in catalase expression 24 hours after lesion 
onset (P<0.05, figure 6D) but had no effect at 48 hours. The expression levels of Gpx1 after 
FC injection were unchanged at 24 hours but significantly increased at 48 hours of 
reperfusion (P<0.001, figure 6E). After FC injection, the Hmox1 levels were increased at 48 
hours of reperfusion compared with the levels in untreated eyes (P<0.05, figure 6F); 
however, the expression levels in FC treated eyes at 48 hours of reperfusion were lower 
than the corresponding levels at 24 hours and followed a similar pattern as that found for 
untreated eyes (P<0.05, figure 6F).  
Expression of neurotrophic factors was changed after ischemia and FC delivery 
The Bdnf levels increased after lesion onset, with peak expression at 12 hours after 
ischemia induction (P<0.05, figure 7A), and then decreased below the basal level at 48 
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hours of reperfusion (P<0.001, figure 7A). Gdnf expression was also increased and was 
highest at 12 hours after ischemia (P<0.001, figure 7A), returning to the basal level at 48 
hours of reperfusion. Ngf levels showed the same pattern of expression and were highest 
at 12 hours post lesion (P<0.001, figure 7A), reaching basal levels at 48 hours after ischemia 
induction. In contrast, Cntf mRNA levels did not change immediately after lesion onset but 
were significantly elevated at 48 hours post lesioning (P<0.001, figure 7A).  
FC injection 12 hours post lesioning led to an additional increase in Bdnf expression at 24 
hours of reperfusion (P<0.05, figure 7B) and a less pronounced decrease in expression at 48 
hours of reperfusion (P<0.001, figure 7B). The same pattern of expression was observed for 
Gdnf (24 hours: P<0.001, 48 hours: P<0.05, figure 7C). Additionally, Ngf expression 
increased at 24 hours after lesion onset and FC treatment (P<0.001, figure 7D). For Cntf, FC 
injection led to a less pronounced increase at 48 hours of reperfusion compared to the 
increase observed in the untreated ischemic eyes (P<0.001, figure 7E).  
 
Discussion 
In this study, we evaluated the effect of transient inhibition of Müller cell metabolism on 
retinal ganglion cell survival after acute ischemia/reperfusion in vivo. We hypothesized that 
impairing Müller cell activation after an ischemic lesion induction would block the 
detrimental effects of the reactive gliotic response, thereby improving neuronal survival 
after lesioning.  
Since there were no data available about the effect of FC in the mouse retina, we first 
evaluated its effectiveness in isolated mouse Müller cells in vitro. FC is a competitive 
inhibitor of aconitase and reversibly blocks the Krebs cycle (Clarke et al. 1970; Peters and 
Shorthouse 1972). FC reduces Müller cell metabolism in the retina of several organisms, 
including rats, chickens and frogs (Virgili et al. 1991; Zeevalk and Nicklas 1997; Jablonski 
and Iannaccone 2000), without adversely affecting the metabolism of neurons (Paulsen et 
al. 1987; Hassel et al. 1992; Hayakawa et al. 2010). In agreement with the aforementioned 
studies, FC specifically reduced Müller cell metabolism in vitro. In vivo, we found a 
significant reduction in aconitase activity at the FC concentration reported for the rat retina 
(Virgili et al. 1991). Similarly in agreement with previous studies, the inhibition of aconitase 
with FC maximally reduced retinal glutamine levels between four and six hours after 
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delivery (Swanson and Graham 1994; Zeevalk and Nicklas 1997). The levels were restored 
24 hours after treatment. 
Next, we determined the effect of Müller cell inhibition on ischemia-induced retinal 
ganglion cell death by delivering FC at various points in time before and after lesion onset. 
Delivery of FC four hours prior to induction of retinal ischemia, as well as immediately or six 
hours after lesion onset, did not affect neuronal survival. However, when delivered 12 
hours after lesion onset, FC significantly improved neuronal survival seven days after 
lesioning. Our results are in agreement with a study by Andreeva et al. (2014) indicating the 
presence of different phases during ischemia/reperfusion injury in the retina. These phases 
might depend on the differential activation of glial cells, as suggested here. Our findings 
further indicate that the detrimental effects of Müller cell activation are present as early as 
12-18 hours after ischemia induction.  
To evaluate the possible mechanisms involved in neuroprotection induced by Müller cell 
inhibition after ischemia, we measured the expression levels of markers known to be 
involved in the retinal damage response. In accordance with previous studies, we found 
increased expression of the intermediate filaments Gfap and vimentin after lesion onset 
(Kim et al. 1998; Wurm et al. 2011). Intermediate filaments stabilize the hypertrophied 
processes of Müller cells and have been proposed to be involved in the signal transduction 
pathways underlying gliosis. In addition, the expression levels of Glast, which is involved in 
the glial and neuronal uptake of glutamate, were reduced during the early reperfusion 
phase but had increased by a later time point, whereas glutamine synthetase, a Müller cell-
specific enzyme, showed a consistent decrease in expression. This is also in line with 
previous studies (Otori et al. 1994; Nishiyama et al. 2000; Kruchkova et al. 2001; Moreno et 
al. 2005). Interestingly, reduced activity of glutamine synthetase is already known to result 
from depressed GLAST expression, which contributes to neuronal damage following 
ischemia induction (Ishikawa et al. 2011).  
Müller cells coordinate inflammation in the retina and produce pro-inflammatory cytokines, 
such as Il-1β and TNF-α which contribute to the ischemia/reperfusion injury (Wang et al. 
2011; Li et al. 2012). Moreover, Müller cells interact with microglia in a bi-directional 
manner, which helps to shape the overall response to injury in the retina (Wang and Wong 
2014). In our study, the expression levels of the pro-inflammatory cytokines Il-1β and Tnf-α 
as well as the microglial/macrophage activation marker Cd68, were significantly higher 
after lesion onset, which is also in agreement with previous reports (Hangai et al. 1995; 
Song et al. 2017; Berger et al. 2008; Scholz et al. 2015; Bae et al. 2016).  
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Ischemia/reperfusion injury is also associated with the excess generation of reactive oxygen 
species (ROS) (Bonne et al. 1998). Here, we evaluated the expression levels of antioxidant 
enzymes catalyzing the conversion of ROS, including Gpx1, Sod1, Sod2, Cat, and Hmox, all 
known to be involved in the response to ischemia. In agreement with other studies and our 
own work, the expression levels of antioxidant enzymes, with the exception of catalase, 
were increased in the retina early after ischemia (Arai-Gaun et al. 2004; Andreeva et al. 
2014; Schultz et al. 2016; Agardh et al. 2006).The increased levels of neurotrophic factors in 
the central nervous system and the neuroretina after an ischemic insult have been 
suggested to be part of an endogenous protective response (Bringmann and Wiedemann 
2011). In agreement with previous studies, we found a transient increase in Bdnf, Gdnf and 
Ngf levels following ischemia-reperfusion (Lönngren et al. 2006; Miyazaki et al. 2001; Yang 
and Duan 2013; Sanchez et al. 2003; Gustavsson et al. 2008).  
The increase in ganglion cell survival after FC delivery found here was accompanied by 
changes in the expression levels of all the aforementioned markers. In particular, Gfap 
expression was significantly reduced both at 24 and 48 hours after lesion onset. Vimentin 
expression, by contrast, was significantly increased at 48 hours after ischemia induction. 
The expression of intermediate filaments in activated Müller cells normally follows the 
same pattern. The selective increase in vimentin might be independent of Müller cells, 
since reactive microglia are known to also overexpress this intermediate filament (Graeber 
et al. 1988; Jiang et al. 2012). Furthermore, FC reduced Glast expression 24 hours after 
lesion onset and reversed the increase observed 48 hours after ischemia induction. 
Importantly, in mice, GLAST takes up approximately 50% of the glutamate (Sarthy et al. 
2005). Whether FC also affects the expression of other glutamate uptake mechanisms in 
the retina is not known. FC treatment also partially reversed the impaired expression of 
glutamine synthetase at 24 but not 48 hours after lesion onset. Changes in the glutamine 
synthetase expression in Müller cells under pathological conditions have been associated 
with changes in IL-1β levels (Shen and Xu 2009). Since FC did not significantly change the 
expression levels of Il-1β it is probably not involved in the FC-mediated effect on glutamine 
synthetase. Alternatively, neurotrophic factors such as BDNF can increase the expression of 
glutamine synthetase (Dai et al. 2012). In our study, we found increased expression of 
several neurotrophic factors, including BDNF (discussed below), after FC treatment, which 
might partially explain the glutamine synthetase increase observed here.  
Since our findings point to a reduced gliotic response after transient Müller cell inhibition, 
we also evaluated the expression of inflammatory and microglial activation markers. The 
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levels of Tnf-α and Cd68 but not of Il-1β were dramatically increased. In a similar study in 
rats, Il-1β expression was reported to peak between 3 and 12 hours after lesion onset 
(Hangai et al. 1995). This could partially explain the lack of effect on Il-1β after FC delivery, 
which showed a maximum effect 18 hours after injury. On the other hand, these data might 
also indicate that the regulation of Il-1β levels is independent of the Müller cell activation 
status after injury. With regard to Tnf-α FC delivery prolonged the lesion-induced increase 
in Tnf-α expression. TNF-α is an inflammatory cytokine that is known to increase in 
concentration after an ischemic injury and to induce neuronal damage (Bae et al. 2016). 
However, TNF-α has also been found to be neuroprotective against glutamate-induced 
excitotoxicity (Marchetti et al. 2004) and to protect RGCs after retinal ischemia induction 
and early after an optic nerve lesion. This effect is probably mediated by Müller cells 
(Fontaine et al. 2002; Mac Nair et al. 2014). Our findings are in line with a study by Li et al., 
(2012) who found a similar response pattern in cultured Müller cells, with increased cell 
viability and reduced levels of NF-κB, IL-1β and Cox-2 but not TNF-α after hypoxic injury and 
post-lesion delivery of lutein, which was shown to have an anti-inflammatory effect.  
Müller cell inhibition further increased the expression of phagocytic Cd68 following injury. 
Although this finding might at first indicate an increased inflammatory response and 
microglial/macrophage activity after FC delivery, CD68 is expressed by 
microglia/macrophages in both the M1 and M2 activation states and is also present in 
TAMs (tumor-associated macrophages), which release many anti-inflammatory, pro-
angiogenic and growth factors (Komohara et al. 2008; Roszer 2015). Furthermore, 
increased microglial/macrophage phagocytic activity has been found to be beneficial and 
neuroprotective after acute inflammatory processes, by removing dead neurons and 
clearing cell debris (Fu et al. 2014). 
Since ischemic pathology is characterized by increased levels of oxidative stress, we 
evaluated the antioxidant response in the ischemic retina after FC delivery. With the 
exception of catalase, the expression levels of all antioxidant enzymes tested were 
significantly increased. Elevated GPX1 has been associated with reduced cell death after 
experimental stroke (Ishibashi et al. 2002). Increased Hmox1 expression in Müller cells has 
been found to play a protective role in retinal ischemia-reperfusion injury in rats (Sun et al. 
2007; Peng et al. 2008; Arai-Gaun et al. 2004; Ulyanova et al. 2001). Additionally, increased 
Sod1 and Sod2 expression has been associated with better neuronal survival after acute 
retinal ischemia (Liu et al. 2012; Schultz et al. 2016). These results indicate that reduced 
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Müller cell reactivity after ischemia induction leads to an improved antioxidant response, 
partially explaining the increased neuronal survival found in this study. 
As already mentioned, neuronal degeneration after ischemia involves the withdrawal of 
neurotrophic factors. Müller cells produce and release bFGF (Wen et al. 1995), BDNF (Seki 
et al. 2005) and GDNF (Harada et al. 2002), a process modulated by microglia through the 
release of NGF, BDNF and CNTF (Harada et al. 2002). Furthermore, in the presence of 
activated microglia, Müller cells express higher mRNA and protein levels of trophic factors, 
such as GDNF and LIF (Wang et al. 2011), which is consistent with the pattern we found in 
our study. With the exception of Cntf, treatment with FC significantly increased the 
expression of growth factors 24 hours after lesion onset. Since CNTF production after 
retinal lesion onset is localized to Müller cells as part of the endogenous neuroprotective 
system in the retina (Honjo et al. 2000), reduced Cntf expression after FC delivery probably 
reflects the reduced metabolic and activation status of Müller cells. Importantly, 
extracellular glutamate can increase neurotrophic factor expression in Müller cells (Taylor 
et al. 2003). The aforementioned halt of the increase in GLAST after FC treatment could 
lead to increased extracellular glutamate levels. In support of this, FC, in addition to the 
well described decrease in glutamine levels, has been shown to significantly increase 
extracellular glutamate levels in the brain, and this is followed by a significant increase in 
NGF mRNA expression (Gwag et al. 1997). This FC-mediated effect is blocked by NMDA 
glutamate receptor antagonists and suggests that NGF mRNA expression is regulated by 
changes in glutamate levels and could partly explain the increase we found after ischemia 
and FC treatment. Whether a similar mechanism is involved in the changes observed in 
BDNF and GDNF needs to be further investigated. Importantly, elevated NGF expression has 
also been localized to microglia (Yang and Duan 2013; Sanchez et al. 2003). In the same 
studies, the increase in NGF was blocked by minocycline, which specifically inhibits 
microglial activity (Yang and Duan 2013).  
Taking these findings together, our study shows that transient metabolic inhibition of 
Müller cells increases neuronal survival in the post-ischemic retina and further strengthens 
the idea that these cells play a central role in ischemia-associated neurodegeneration. 
Increased neuronal survival was associated with a reduced gliotic response and increased 
antioxidant defense mechanisms and neurotrophic support, thereby promoting a neuronal 
protective environment 12 hours after lesion onset. Our results support the notion that the 
detrimental effects of reactive gliosis can be inhibited to improve neuronal survival. There 
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are only a few reports on the reversibility of reactive gliosis in retinal degenerative 
conditions (Ganesh and Chintala 2011; Livne-Bar et al. 2016; Tura et al. 2009). 
Whether the modulation of Müller cell metabolism will also be neuroprotective in chronic 
degenerative diseases such as glaucoma remains to be investigated. This study supports the 
concept that glial cells constitute a feasible therapeutic target to overcome neuronal 
damage following an acute ischemic lesion. Furthermore, we propose that a combined 
therapy targeting neuronal and glial elements would significantly improve neuronal survival 
after injury.  
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Table 1. Primer sequences used in the study, together with the expected product length 
 Primer sequence Product size  
Gliosis    
Gfap fw 5' AGAAAGGTTGAATCGCTGGA 3' 176 bp 
 re 5' GCCACTGCCTCGTATTGAGT 3'  
Vim fw 5' TGAAGGAAGAGATGGCTCGT 3' 194 bp 
 re 5' GGTGTCAACCAGAGGAAGTGA 3'  
Glast fw 5' GCCCTCCGACCGTATAAAAT 3' 128 bp 
 re 5' GCCATTCCTGTGACGAGACT 3'  
Glul fw 5' ATCGGGTGTGCGAAGACTTT 3' 181 bp 
 re 5' CGAATGTGGTACTGGTGCCT 3'  
Inflammation    
TNF-α fw 5' GTCTACTGAACTTCGGGGTGAT 3' 102 bp 
 re 5' ATGATCTGAGTGTGAGGGTCTG 3'  
Il-1β fw 5' GAAGAGCCCATCCTCTGTGA 3' 96 bp 
 re 5' TTCATCTCGGAGCCTGTAGTG 3'  
Cd68 fw 5' TTCTGCTGTGGAAATGCAAG 3' 116 bp 
 re 5' GAGAAACATGGCCCGAAGT 3'  
Antioxidant enzymes   
Sod1 fw 5' GTCCGTCGGCTTCTCGTCT 3' 163 bp 
 re 5' CACAACTGGTTCACCGCTTG 3'  
Sod2 fw 5' ATTAACGCGCAGATCATGCA 3' 161 bp 
 re 5' TGTCCCCCACCATTGAACTT 3'  
Cat fw 5' GCAGATACCTGTGAACTGTC 3' 229 bp 
 re 5' GTAGAATGTCCGCACCTGAG 3'  
Gpx1 fw 5' GGGACTACACCGAGATGAACGA 3' 197 bp 
 re 5' ACCATTCACTTCGCACTTCTCA 3'  
Hmox-1 fw 5' GGTGATGGCTTCCTTGTACC 3' 155 bp 
 re 5' AGTGAGGCCCATACCAGAAG 3'  
Neurotrophic factors   
Bdnf fw 5' TGGCTGACACTTTTGACCAC 3' 131 bp 
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fw, forward primer; re, reverse primer; bp, base pairs. 
 re 5' CAAAGGCACTTGACTGCTGA 3'  
Gdnf fw 5' TGGGCTATGAAACCAAGGAG 3' 142 bp 
 re 5' CAACATGCCTGGCCTACTTT 3'  
Ngf fw 5' AGCATTCCCTTGACACAG 3' 99 bp 
 re 5' GGTCTACAGTGATGTTGC 3'  
Cntf fw 5' ATGACTGAGGCAGAGCGACT 3' 157 bp 
 re 5' AGGCAGAAACTTGGAGCGTA 3'  
Housekeeping genes   
Hprt fw 5' TGACACTGGTAAAACAATGCA 3' 94 bp 
 re 5' GGTCCTTTTCACCAGCAAGCT 3'  
Gapdh fw 5' AGGTCGGTGTGAACGGATTTG 3' 123 bp 
 re 5' TGTAGACCATGTAGTTGAGGTCA 3'  
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Table 2. Expression levels of selected markers at various time points during reperfusion after transient retinal 
ischemia with and without FC treatment (mean ± SEM)  
 Gliosis marker 
  Gfap Vim Glast Glul   
Control 1.00 ± 0.04 1.00 ± 0.04 1.00 ± 0.01 1.00 ± 0.04  
12 h reperfusion 2.84 ± 0.29 * 4.31 ± 0.18 ** 0.71 ± 0.03 * 0.44 ± 0.03 **  
24 h reperfusion 5.76 ± 0.23 * + 5.58 ± 0.17 * 1.21 ± 0.04 ++ 0.38 ± 0.03 *  
48 h reperfusion 14.55 ± 2.74 * + § 4.09 ± 0.58 * 2.54 ± 0.29 ** ++ §§ 0.42 ± 0.08 *  
      
24 h reperfusion + FC 3.71 ± 0.18 § 5.65 ± 0.08 0.56 ± 0.04 §§ 0.62 ± 0.01 §  
48 h reperfusion + FC 7.71 ± 0.34 & %% 8.26 ± 0.77 && % 1.22 ± 0.06 && %% 0.34 ± 0.03 %  
      
 Inflammatory markers 
  Tnf-α Il-1β Cd68    
Control 1.01 ± 0.11 1.00 ± 0.04 1.00 ± 0.06   
12 h reperfusion 18.68 ± 1.33 ** 35.08 ± 2.83 * 5.04 ± 0.32 **   
24 h reperfusion 23.96 ± 7.87 ** 12.24 ± 2.24 * ++ 6.69 ± 0.23 ** +   
48 h reperfusion 10.80 ± 1.87 ** + § 8.58 ± 3.94 ** + 8.09 ± 1.05 ** +   
      
24 h reperfusion + FC 24.2 ± 0.71 9.84 ± 3.63  10.6 ± 1.06 §   
48 h reperfusion + FC 26.1 ± 2.21 & 5.64 ± 0.56 12.9 ± 0.78 &   
      
 Antioxidant enzymes 
  Sod1 Sod2 Cat Gpx1 Hmox1 
Control 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.02 1.00 ± 0.03  1.00 ± 0.04 
12-h reperfusion 1.11 ± 0.03 * 1.29 ± 0.04 ** 0.78 ± 0.07 * 1.20 ± 0.02 * 19.33 ± 3.53 ** 
24 h reperfusion 1.33 ± 0.02 ** ++ 1.27 ± 0.03 ** 1.18 ± 0.05 * ++ 1.77 ± 0.05 ** ++ 11.97 ± 2.84 ** 
48 h reperfusion 1.19 ± 0.02 ** § 0.97 ± 0.01 ++ §§ 1.45 ± 0.04 ** ++ § 2.00 ± 0.15 ** ++ 4.86 ± 1.09 ** ++ § 
      
24 h reperfusion + FC 1.52 ± 0.03 §§ 1.41 ± 0.01 §§ 1.04 ± 0.03 § 1.58 ± 0.04 17.97 ± 0.7 
48 h reperfusion + FC 1.67 ± 0.04 && % 1.20 ± 0.02 && %% 1.44 ± 0.06 %% 3.04 ± 0.11 && %% 9.72 ± 0.90 § % 
      
 Neurotrophic factors 
  Bdnf Gdnf Ngf Cntf  
Control 1.00 ± 0.10 1.00 ± 0.04 1.00 ± 0.07 1.00 ± 0.04  
12 h reperfusion 1.39 ± 0.04 * 5.78 ± 0.53 **  2.04 ± 0.18 ** 0.99 ± 0.08  
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24 h reperfusion 1.25 ± 0.05 * 1.81 ± 0.37*++ 1.29 ± 0.04 + 1.20 ± 0.05  
48 h reperfusion 0.60 ± 0.05 ** ++ § 0.91 ± 0.07 ++ § 1.12 ± 0.13 ++ 3.15 ± 0.25 ** ++ §§  
      
24 h reperfusion + FC 1.78 ± 0.18 § 7.36 ± 0.75 §§ 2.91 ± 0.37 §§ 1.43 ± 0.13  
48 h reperfusion + FC 1.03 ± 0.04 && %% 1.44 ± 0.22 & %% 1.40 ± 0.17 % 1.65 ± 0.08 &&  
** P<0.001, * P<0.05 vs. naïve control 
++ P<0.001, + P<0.05 vs. 12 hours of reperfusion  
§§ P<0.001, § P<0.05 vs. 24 hours of reperfusion  
&& P<0.001, & P<0.05 vs. 48 hours of reperfusion  
%% P<0.001, % P<0.05 vs. 24 hours reperfusion with FC 
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Figure legends 
Figure 1. Experimental design for intravitreal FC administration and metabolic inhibition of 
Müller cells from female C57BL/6 mice in vivo. Mice were sacrificed 12, 24 and 48 hours 
after treatment for qRT-PCR analysis or after 7 days to quantify surviving RGCs after lesion. 
Figure 2. Efficacy of different dosages of FC in vitro and in vivo. A) MTT assay with cultured 
primary Müller cells. Absorbance was assayed 4, 6, 12 and 24 hours after FC treatment. 
Bars represent the mean ± SEM. One-way ANOVA. *P<0.05 vs. Müller cellsl cells treated 
with saline; n = 6. B) Aconitase activity 4 hours after intravitreal injection of FC or saline. 
Aconitase activity was determined over a period of 50 min. Values were corrected against 
blank measurements. Measurement points represent the mean ± SEM. One-way ANCOVA, 
P<0.05, n = 4. C) Time-dependent effects of FC on glutamine levels in the retina. Glutamine 
levels are expressed as percentage of those in naïve control eyes. One-way ANOVA, P<0.05 
vs. control. Bars represent the mean ± SEM, n = 5. 
Figure 3. Effect of FC treatment on RGC survival 7 days after acute retinal 
ischemia/reperfusion. A) Retinal whole-mount preparations from unlesioned, lesioned and 
FC-treated animals. Images were taken near the optic nerve by means of laser scanning 
microscopy (Zeiss LSM 710). Scale bars represent 50 µm. B) Analysis of surviving RGCs after 
acute retinal ischemia. Numbers of RGCs are expressed as percentages of contralateral 
eyes. Cell counts were determined 7 days after ischemia in retinae treated with FC at 
different points in time before and after lesion onset (FC -4 h: treatment 4 hours before 
lesion onset, FC 0 h: treatment at reperfusion onset, FC +6 h/FC +12 h: treatment at late 
reperfusion. One-way ANOVA ***P<0.001 vs. unlesioned control, +++ P<0.001 vs. FC + 12 h; 
Bars represent the mean ± SEM, n = 5. 
Figure 4. Effect of acute retinal ischemia/reperfusion and FC treatment on mRNA levels of 
gliosis markers. A) Expression levels of corresponding mRNAs were determined 12, 24 and 
48 hours after ischemia by quantitative polymerase chain reaction and normalized against 
Gapdh and Hprt. Logarithmic scaling; bars represent the mean ± SEM, n = 4. One-way 
ANOVA, *** P<0.001; * P<0.05. B-E) Effects of FC on Gfap, Vim, Glast and Glul expression 
levels are depicted as the ratio of treated vs. naïve corresponding control eyes. mRNA levels 
were determined 24 hours and 48 hours after ischemia and FC treatment. Bars represent 
the mean ± SEM, n = 4, Two-way ANOVA, *** P<0.001; * P<0.05. 
Figure 5. Effect of acute retinal ischemia/reperfusion and FC treatment on mRNA levels of 
inflammatory markers. A) Expression levels of corresponding mRNA were determined 12, 
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24 and 48 hours after ischemia by quantitative polymerase chain reaction and normalized 
to Gapdh and Hprt. Logarithmic scaling, bars represent the mean ± SEM, n = 4. One-way 
ANOVA, *** P<0.001; * P<0.05. B-D) Effects of FC on Tnf-α, Il-1β, and Cd68 expression 
levels are depicted as the ratio of treated vs. naïve corresponding control eyes. mRNA levels 
were determined 24 hours and 48 hours after ischemia and FC treatment. Bars represent 
the mean ± SEM, n = 4. Two-way ANOVA, *** P<0.001; * P<0.05. 
Figure 6. Effect of acute retinal ischemia/reperfusion and FC treatment on mRNA levels of 
antioxidant enzymes. A) Expression levels of corresponding mRNAs were determined 12, 24 
and 48 hours after ischemia by quantitative polymerase chain reaction and normalized 
against Gapdh and Hprt. Logarithmic scaling for Hmox1; bars represent the mean ± SEM, n 
= 4. One-way ANOVA, *** P<0.001; * P<0.05. B-F) Effects on Sod1, Sod2, Cat, Gpx1 and 
Hmox1, expression are depicted as the ratio of treated vs. naïve corresponding control 
eyes. mRNA levels were determined 24 hours and 48 hours after ischemia and FC 
treatment. Bars represent the mean ± SEM, n = 4. Two-way ANOVA, *** P<0.001; * P<0.05. 
Figure 7. Effect of acute retinal ischemia/reperfusion and FC treatment on mRNA levels of 
neurotrophic factors. A) Expression levels of corresponding mRNAs were determined 12, 24 
and 48 hours after ischemia by quantitative polymerase chain reaction and normalized 
against Gapdh and Hprt. Bars represent the mean ± SEM, n = 4. One-way ANOVA, *** 
P<0.001; * P<0.05. B-F) Effects of FC on Bdnf, Gdnf, Ngf and Cntf expression are depicted as 
the ratio of treated vs. naïve corresponding control eyes. mRNA levels were determined 24 
hours and 48 hours after ischemia and FC treatment. Bars represent the mean ± SEM, n = 4. 
Two-way ANOVA, *** P<0.001; * P<0.05. 
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Abstract 
Müller cells are critical for retinal function and neuronal survival but can become 
detrimental in response to retinal ischemia and increased oxidative stress. Elevated 
oxidative stress increases expression of the mitochondrial enzyme frataxin in the retina, 
and its overexpression is neuroprotective after ischemia. Whether frataxin expression in 
Müller cells might improve their function and protect neurons after ischemia is unknown. 
The aim of this study was to evaluate the effect of frataxin overexpression in Müller cells on 
neuronal survival after retinal ischemia/reperfusion in the mouse in vivo. 
Retinal ischemia was induced in mice overexpressing frataxin in Müller cells by transient 
elevation of intraocular pressure. Retinal ganglion cells survival was determined 14 days 
after lesion. Expression of frataxin, antioxidant enzymes, growth factors and inflammation 
markers was determined with qRT-PCR, Western blotting and immunohistochemistry 24 
hours after lesion.  
Following lesion, there was a 65% increase in the number of surviving RGCs in frataxin 
overexpressing mice. Improved survival was associated with increased expression of the 
antioxidant enzymes Gpx1 and Sod1 as well as the growth factors Cntf and Lif. Additionally, 
microglial activation was decreased in these mice. 
Therefore, support of Müller cell function constitutes a feasible approach to reduce 
neuronal degeneration after ischemia. 
 
Introduction 
Glaucoma is the leading cause of irreversible blindness, and due to the complexity of 
pathological mechanisms involved, there are no clinically effective treatments available so 
far. One key element of the pathologic alteration in glaucoma and retinal 
ischemia/reperfusion injury is the generation of excessive reactive oxygen species (ROS) 
during reperfusion. Retinal glia (i.e., Müller cells and astrocytes) play a fundamental role in 
maintaining redox homeostasis and are equipped with tools to resolve redox imbalance1,2. 
Müller cells are the predominant glia in the vertebrate retina, expand the entire retina 
forming a structural scaffolding and have cell contacts to all neuronal cell types in the 
different retinal layers. Therefore they can form a functional unit with a more critical role 
than for astrocytes, which are restricted to the nerve fiber layer1. After injury, Müller cells 
become reactive and participate in glial scar formation. Interestingly, metabolic support of 
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neurons by Müller cells has been shown to be compatible, even with proliferative reactive 
gliosis induced in mice3. However, morphological and functional alterations in the MG have 
been found under ischemic conditions or elevated levels of oxidative stress4, which 
probably compromise their supportive role.  
Mitochondria are the main source of free radical production in the cell, under both, normal 
and ischemic conditions5,6. Following ischemic injury, endogenous mechanisms of cellular 
defense are activated to minimize damage. These include superoxide dismutases (SODs), 
glutathione, vitamins A, C, and E, catalase and other peroxidases. Moreover, recent 
evidence supports a role for the mitochondrial protein frataxin (FXN) in various diseases, 
which are caused by increased oxidative stress. FXN deficiency is closely associated with 
increased oxidative stress damage in Friedreich ataxia (FRDA), an autosomal recessive 
disease characterized by progressive neurodegeneration in the spinal cord and 
hypertrophic cardiomyopathy7–9. FXN acts as an important regulator of mitochondrial 
energy metabolism10,11 and is involved in several important functions including cellular iron 
homeostasis and redox balance during oxidative stress7. The mature FXN protein is highly 
expressed in mitochondria of metabolically active tissues such as liver, skeletal and cardiac 
muscle, and brain12. In the adult mouse retina, immunoreactivity to FXN has been shown in 
the external and internal plexiform layers, the ganglion cell layer and the internal nuclear 
layer. Highest levels of FXN were observed in internal segments of the photoreceptor 
cells13.  
Improving essential functions of glia was shown to augment glial support to retinal 
neurons1. In particular, support of the glial management of retinal redox homeostasis has 
been proposed as a therapeutic alternative to overcome neuronal degeneration due to 
excessive oxidative stress1. Because Müller cells span the entire retina and quickly respond 
to injury, they are ideal targets for therapeutic strategies, including gene therapy14. Delivery 
of exogenous antioxidants or the manipulation of antioxidant pathways within the retina 
favors the interaction between retinal glia and neurons, and improves RGC survival and 
function1,15. In particular, FXN overexpression was found to stimulate the production of ATP 
and to induce the activation of antioxidant mechanisms8. In a previous study, we found an 
increased expression of endogenous FXN in the mouse retina 24 hours after an ischemic 
lesion, indicating that FXN is involved in neuroprotective mechanisms in response to 
ischemic retinal injury16. Furthermore, in the same study, we showed that ubiquitous 
overexpression of human FXN under the transcriptional control of a human 
cytomegalovirus (CMV) minimal promoter resulted in neuronal protection. Neuroprotection 
was associated with changes in expression levels of some stress response molecules, 
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including Hmox1 and Hif-2α which suggested the participation of glial cells, particularly 
Müller cells, in FXN-mediated neuroprotection. To further evaluate the cellular mechanisms 
involved in the FXN-mediated neuroprotection in the ischemic retina and the putative role 
of Müller cells, here we used a conditional transgenic mouse model overexpressing the 
human FXN gene specifically in these cells.  
 
Results 
FXN expression was increased in the retina of naïve MGCre-FXN mice and specifically 
localized to Müller cells  
To evaluate the effect of FXN overexpression in Müller cells on neuronal survival after 
ischemia, we generated transgenic mice specifically expressing the human FXN cDNA and 
EGFP transcript in Müller cells (referred to as MGCre-FXN mice, see materials and 
methods).  
Quantification of mRNA for both, murine and human FXN, showed specific expression of 
the human FXN transcript in the retina of FXN overexpressing mice (Fig. 1A) and increased 
levels for endogenous mouse FXN compared with MGCre-B6 mice (1.00 ± 0.05 vs. 1.50 ± 
0.11-fold increase, P < 0.001). The Western blot analysis showed higher levels of expression 
for both, precursor (30 kDa) and mature FXN protein (18 kDa) in MGCre-FXN mice, 
compared to MGCre-B6 mice (45% and 65% increase respectively, P<0.05, Fig. 1B). 
However, human FXN protein was indistinguishable from the endogenous mouse variant 
(Fig. 1B’). 
To prove the cellular localization of human FXN, retinal slices were co-stained with anti-GFP 
and the Müller cell-specific marker glutamine synthetase (GLUL). EGFP was specifically 
localized in cells spanning the whole retina from FXN overexpressing mice (Fig. 1C). The 
expression of EGFP was co-localized with the specific Müller cells marker GLUL in the retina 
from the MGCre-FXN mice (Fig. 1C-C’’) and was detected in 41 ± 8% of all retinal Müller 
cells. 
Gene expression of oxidative stress-related markers was altered in naïve MGCre-FXN 
mice 
First, we evaluated whether FXN overexpression leads to changes in gene expression in 
naïve MGCre-FXN mice. In the study we focused on markers well known to be involved in 
the retinal response and neuronal protection after lesion. These include neurotrophic 
factors such as leukemia inhibitory factor (Lif), nerve growth factor (Ngf), brain-derived 
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neurotrophic factor (Bdnf), ciliary neurotrophic factor (Cntf) and glial cell line-derived 
neurotrophic factor (Gdnf), antioxidant enzymes including glutathione peroxidase 1 (Gpx1), 
superoxide dismutase [Cu-Zn] (Sod1), superoxide dismutase [Mn] (Sod2), catalase (Cat) and 
heme oxygenase 1 (Hmox-1), gliosis and inflammation markers including vimentin (Vim), 
glial fibrillary acidic protein (Gfap), glutamate aspartate transporter (Glast), glutamine 
synthetase (Glul), tumor necrosis factor alpha (Tnf-α) and Interleukin 1 beta (Il-1β). We 
measured the relative mRNA expression by means of qRT-PCR and compared the values 
against those obtained in naïve non-transgenic MGCre-B6 mice.  
The expression levels of the growth factor Bdnf were significantly increased, whereas mRNA 
levels of Cntf and Lif were decreased in naïve MGCre-FXN mice compared with control 
MGCre-B6 mice (Bdnf: 1.22 ± 0.02-fold increase, P < 0.001; Cntf: 0.83 ± 0.01-fold decrease, 
P < 0.001; Lif: 0.41 ± 0.02-fold decrease, P < 0.05, Fig. 2). The inflammation marker Tnf-α 
was significantly decreased in naïve transgenic retinae (0.55 ± 0.06-fold decrease, P < 0.05, 
Fig. 2) and the antioxidative enzyme Cat was significantly increased (1.16 ± 0.07-fold 
increase, P < 0.05, Fig. 2). Furthermore, the glia marker Vim, which is upregulated during 
gliosis, was decreased in naïve MGCre-FXN mice (0.66 ± 0.05 vs. 1.00 ± 0.03-fold decrease, P 
< 0.05, Fig. 2). The other markers tested did not differ in naïve MGCre-FXN compared with 
MGCre-B6 mice. 
FXN overexpression in Müller cells increased RGC survival after ischemia  
We next examined whether the expression of FXN in Müller cells increased survival of RGCs 
after acute transient retinal ischemia. In naïve retinae from both, MGCre-FXN and MGCre-
B6 mice, RGC distribution was highest around the optic nerve (1/6 from retinal radius) and 
decreased towards the periphery (5/6 from retinal radius). No differences in the overall cell 
distribution were observed between strains (Fig. 3A/B, Table 2). 
After lesion, the number of RGCs decreased in MGCre-B6 and MGCre-FXN mice to 35 ± 2% 
(P < 0.001; n = 6) and 58 ± 6% (P < 0.001; n = 8) respectively, compared with non-lesioned 
control eyes (Fig. 3B’). This represents an increased RGC survival in mice overexpressing 
FXN of 65% 14 days after ischemia compared with MGCre-B6 mice (P < 0.05, Fig. 3B’). 
Interestingly, as illustrated in Fig. 4A, the retinal thickness was increased in non-lesioned 
MGCre-FXN mice compared with control animals. In particular, thickness of the GCL/IPL, as 
well as the INL, was increased by 24% and 13%, respectively. This was accompanied by a 
slight, but significant increase of basal IOP in naïve MGCre-FXN mice (16 ± 0.3 mmHg vs. 14 
± 0.3 mmHg, P < 0.05, Fig. 4B). 
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Retinal ischemia significantly reduced the thickness of the GCL/IPL by approximately 20% 
on average in MGCre-FXN mice compared with MGCre-B6 animals. Despite an increased 
neuronal survival, no differences in retinal thickness were found between strains after 
injury (Fig. 4A/C).   
Increased expression of antioxidant enzymes in MGCre-FXN mice after ischemia 
Gene expression ratios of the antioxidant enzymes Gpx1, Sod1 and Sod2, Cat and Hmox1 
were evaluated 24 hours after ischemia by means of qRT-PCR to determine whether 
increased antioxidative capacity might be involved in FXN-mediated neuroprotection.  
The expression levels of all enzymes evaluated were significantly increased in MGCre-B6 
mice after lesion compared to basal levels (Gpx1: 1.60 ± 0.05-fold increase, P<0.001; Sod1: 
1.16 ± 0.03-fold increase, P<0.001; Sod2: 1.20 ± 0.02-fold increase, P<0.001; Cat: 1.31 ± 
0.02-fold increase, P<0.001; Hmox1: 9.44 ± 0.72-fold increase, P<0.001).  
All tested markers also increased above basal levels in MGCre-FXN mice after lesion, (Gpx1: 
1.89 ± 0.05-fold increase, P<0.001; Sod1: 1.33 ± 0.06-fold increase, P<0.001; Sod2: 1.16 ± 
0.05-fold increase, P<0.001; Cat: 1.33 ± 0.03-fold increase, P<0.001; Hmox1: 9.44 ± 1.56-
fold increase, P<0.001). In addition, the expression levels of Gpx1 and Sod1 were 
significantly higher in MGCre-FXN mice compared with the MGCre-B6 animals after injury 
(P<0.05; Fig. 5A).  
Expression of neurotrophic factors is altered in MGCre-FXN mice after lesion 
To evaluate the role of growth factors in FXN-mediated neuroprotection, changes in 
expression of the growth factors Gdnf, Ngf, Bdnf, Cntf and Lif were analyzed 24 hours after 
ischemia by means of qRT-PCR. 
The expression levels of Ngf, Bdnf, Cntf and Lif were significantly increased in MGCre-B6 
mice (Ngf: 1.60 ± 0.11-fold increase, P < 0.001; Bdnf: 1.43 ± 0.03-fold increase, P<0.001; 
Cntf: 1.39 ± 0.09-fold increase, P < 0.001; Lif: 8.44 ± 0.65-fold increase, P<0.001).  
In MGCre-FXN mice, all measured factors were also increased above basal levels 24 hours 
after ischemia (Ngf: 1.59 ± 0.16-fold increase, P<0.001; Bdnf: 1.36 ± 0.03-fold increase, 
P<0.001; Cntf: 1.8 ± 0.16-fold increase, P < 0.001; Lif: 4.71 ± 1.06-fold increase, P < 0.001).  
Moreover, Cntf expression was higher and Lif expression was lower in MGCre-FXN mice 
compared with MGCre-B6 animals (P < 0.05; Fig. 5B). 
Expression levels of inflammation and gliosis marker are not different between MGCre-
FXN and MGCre-B6 mice after lesion 
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Expression of the cytokines Tnf-α and Il-1β and of the gliosis marker Glast, Vim, Glul and 
Gfap were evaluated 24 hours after ischemia by means of qRT-PCR to determine whether 
inflammation or an altered gliotic response is involved in FXN-mediated neuroprotection.  
Pro-inflammatory cytokines were significantly increased in MGCre-B6 mice after lesion 
compared to basal levels (Tnf-α: 6,20 ± 0.42-fold increase, P<0.001; Il-1β: 1.73 ± 0.21-fold 
increase, P<0.001). The expression levels of the intermediary filaments Gfap and Vim were 
increased after lesion, as well as the mRNA levels of Glast (Gfap: 14.04 ± 0.97-fold increase, 
P<0.001; Vim: 5.47 ± 0.31-fold increase, P<0.001; Glast: 1.50 ± 0.08-fold increase, P<0.001). 
Glul levels decreased after ischemia (0.28 ± 0.01-fold decrease, P<0.001). 
In MGCre-FXN mice, inflammatory markers were also increased above basal levels after 
lesion (Tnf-α: 6,82 ± 0.97-fold increase, P<0.001; Il-1β: 1.62 ± 0.48-fold increase, P<0.001). 
Expression of the intermediary filaments Gfap and Vim as well as the levels of Glast were 
increased after injury (Gfap: 18.03 ± 2.97-fold increase, P<0.001; Vim: 4.63 ± 0.53-fold 
increase, P<0.001; Glast: 1.49 ± 0.12-fold increase, P<0.001). Glul levels decreased after 
ischemia (0.30 ± 0.04-fold decrease, P<0.001). 
No differences in the expression of these markers were detected between MGCre-B6 and 
MGCre-FXN mice after ischemia. 
Microglia response was impaired in MGCre-FXN mice after lesion 
Müller cells and microglia communicate via bidirectional signaling that can mediate 
adaptive responses within the retina following injury17. To determine whether FXN 
expression in Müller cells might influence the microglia response, we evaluated the 
distribution of Iba1+ microglia and expression of the activation markers CD68 and MHCII in 
retinal slices before and after lesion. CD68 is a lysosomal protein and can be used to stain 
microglia in the retina. High expression levels are associated with macrophages and 
reactive microglia, while low levels of expression are associated with quiescent ramified 
microglia18–20. In addition, reactive microglia express the major histocompatibility complex 
class II (MHCII) for antigen presentation21,22. 
No differences in the number of Iba1+ microglia were observed in naïve retinae of MGCre-
B6 and MGCre-FXN mice (16 ± 2 and 14 ± 1 cells/1000µm, respectively, P < 0.001, Fig. 6 and 
Fig.7A). Few CD68 (4.5 ± 1% and 8.3 ± 1%, respectively) positive and almost no MHCII 
positive microglia were found (2.8 ± 1% and 4.1 ± 1%, respectively, Fig. 6 and Fig. 7). 
After ischemia, the percentage of Iba1+/Cd68+ microglia strongly increased in both, 
MGCre-B6 and MGCre-FXN mice; however, in MGCre-FXN mice the number of CD68+ 
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microglia was lower compared with MGCre-B6 mice (56 ± 9% vs. 81.1 ± 1%; P<0.05; Fig. 7B). 
The number of MHCII+ microglia after lesion increased only in MGCre-B6 mice (7.8 ± 2% vs. 
2.8 ± 1%; P<0.05; Fig. 7C).  
 
Discussion 
In the present work, we generated a mouse model overexpressing human FXN specifically 
in retinal Müller cells. Naïve transgenic mice showed slightly decreased expression of gliosis 
and inflammation markers and of neurotrophic factors. After ischemia, we found an 
increased RGC survival in transgenic mice overexpressing FXN. Improved cell survival 
correlated with an increase in gene expression of antioxidant enzymes and neurotrophic 
factors, whereas the activity of retinal immune cells (microglia) was reduced. 
In FXN overexpressing mice the expression levels of hFXN mRNA and FXN protein levels 
were significantly elevated in lysates from the whole retina. These data are similar to 
results obtained in a previous study using a transgenic mouse model with ubiquitous FXN in 
all retinal cells16. FXN overexpression was specifically increased in about 41% of all Müller 
cells. This value is similar to data shown in a previous study using the same Cre-
recombinase expressing mice model23. Naïve transgenic animals did no show differences in 
the number or distribution of RGCs and microglia as compared with MGCre-B6 animals; 
however, morphological analysis of the naïve retina from FXN overexpressing mice showed 
an overall increase in retinal thickness, mainly manifested in the GCL and IPL but also in the 
INL. We also found a slight but significant increase in basal IOP levels in these animals. 
Different IOP levels ranging from an IOP of 11.1 ± 0.5 mmHg to 19.3 ± 0.3 mmHg have been 
described in several different mouse strains, and have not been associated to 
morphological changes or development of glaucoma24.  
Retinae without Müller cells have decreased resistance to tensile stress rendering the 
retinal tissue to rip apart, a defect known as retinoschisis. FXN overexpression, seems to 
induce a similar effect by reducing the tensile strength of Müller cells, resulting in expanded 
retinal layers. The underlying mechanism is unknown, but could involve reduced levels of 
the intermediate filament vimentin and slight increased IOP levels found in these animals. 
Vimentin deficiency and mechanical stress have already been associated with a local 
separation of the inner limiting membrane leading to an increased retinal thickness25. 
There are only a few reports on transgenic mice strains overexpressing FXN and its 
associated effects. Mice expressing the full-length human FXN cDNA are normal with no 
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signs of ataxia or other obvious abnormalities11,26; however, these mice have an altered 
response during hematopoietic differentiation26, The retina was not evaluated in that 
mouse model. For FXN overexpression, the existing literature presents contradictory 
results. On the one hand, experiments in vivo or in vitro in mice revealed that FXN 
overexpression was innocuous or had a positive effect on cell metabolism, stimulating the 
production of ATP or activating antioxidant mechanisms11,16,26–28. In addition, 
overexpression of FXN in Drosophila promoted cellular resistance to oxidative stress8. On 
the other hand, FXN overexpression can lead to detrimental phenotypes in Drosophila, 
including developmental defects, a decrease in the level of aconitase activity, 
hypersensitivity to oxidative stress29, and reduced viability and impaired embryonic 
development of muscles and the peripheral nervous system30. Interestingly, overexpression 
of FXN in yeast has also been shown to critically reduce aconitase activity, leading to 
impaired [Fe-S] cluster assembly and respiration31. The mechanisms responsible for these 
effects are not known, but FXN aggregation and a misfolding of the protein have been 
shown to not be the cause for the phenotypes that have been observed30. Importantly, also 
in yeast, frataxin overproduction increased cellular antioxidant defenses31. In our study, 
FXN overexpression in Müller cells led to changes in the basal gene expression of several 
factors. Increased Cat might improve retinal homeostasis by providing a less oxidative 
environment, as also suggested by decreased Lif expression28. BDNF levels are known to be 
associated with increased expression of antioxidant proteins and reduced oxidative stress 
levels32,33. Therefore, increased Bdnf levels in naïve FXN overexpressing mice might also be 
indicative of decreased ROS levels, even before lesion onset. 
Transient retinal ischemia leads to a high loss of RGCs in MGCre-B6 mice, comparable to 
values obtained in a previous study from our lab using C57BL/6J mice16. Here, we show for 
the first time that specific FXN overexpression in Müller cells leads to a significant increase 
in neuronal survival after lesion. Interestingly, we achieved the same level of 
neuroprotection compared with transgenic mice with ubiquitous FXN overexpression in the 
retina16. This strongly indicates that Müller cells play a critical role in neuroprotection after 
the ischemic lesion.  
One of the hallmarks of acute retinal ischemia/reperfusion is the generation of excessive 
ROS leading to neuronal cell death. Müller cells are well known to protect neuronal cells 
from oxidative stress by providing antioxidants such as glutathione34. Since protective 
effects mediated by FXN overexpression are known to also involve several antioxidant 
mechanisms26,28, we tested the effect of increased FXN expression on levels of antioxidant 
enzymes, including Gpx1, Sod1, Sod2, Cat, and Hmox1. The expression of all enzymes was 
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increased in the retinae of both MGCre-B6 and MGCre-FXN mice after ischemia, in 
agreement with other studies2,35,36. Importantly, Gpx1 and Sod1 were expressed more 
highly in transgenic mice than in MGCre-B6 mice. Both factors are already described to be 
neuroprotective37,38. These results are also in agreement with our previous study involving 
FXN overexpression in the retina, where we found increased levels of Gpx1, Sod1, Sod2 and 
Cat transcripts after lesion16. This supports our previous findings showing that FXN 
mediates neuroprotection after ischemia by promoting the antioxidant response. To 
evaluate further mechanisms involved in neuroprotection by FXN expression in Müller cells, 
we measured the expression levels of growth factors, including Bdnf, Gdnf, Ngf, Lif and 
Cntf. Neurotrophic factors are known to have neuroprotective properties39 and have been 
suggested to be part of an endogenous response mechanism after an ischemic insult40. In 
agreement with other studies, we found an increase in Bdnf, Ngf, Lif and Cntf levels 
following ischemia-reperfusion in both MGCre-B6 and FXN overexpressing mice41–45. 
Interestingly, in our study, only Cntf increased significantly over nontransgenic levels after 
lesion. CNTF has been described to be neuroprotective for photoreceptor cells46–48 and 
RGCs in several studies49–52. In the retina, CNTF is expressed by various cells and particularly 
by Müller cells53. Increased Cntf transcripts strongly support an important role of Müller 
cells in FXN-mediated neuroprotection. In contrast, Lif transcripts did not reach the 
expression level of nontransgenic animals after lesion. However, it was significantly 
increased above transgenic basal levels. LIF is an important endogenous neuroprotective 
factor in the retina54,55. Specifically, photoreceptor injuries induce a subset of Müller cells to 
express Lif54. Further, it’s transcript seems to be stabilized by H2O256. Together with the 
increased antioxidative response, these results indicate that FXN potentiates Müller cell-
mediated neuroprotection after acute retinal ischemia/reperfusion by increasing the 
neurotrophic support.  
Our results show a decreased microglia response after transient ischemia in transgenic mice 
overexpressing FXN in Müller cells. In models of RGC damage, the extent of microgliosis 
negatively correlates with the number of surviving RGCs57. A decreased number of microglia 
would be expected with increased neuronal survival; however, we did not observe 
differences in microglial numbers after lesion in nontransgenic and transgenic mice. 
Interestingly, the number of reactive microglia, as indicated by the expression of CD68 and 
MHCII, was decreased in FXN overexpressing mice after ischemia. CD68 and MHCII are 
markers of microglia activation19–22,58. Microglia reactivity and inflammation are common 
hallmarks of a broad spectrum of retinal diseases and contribute to RGC loss associated 
with ON damage in glaucoma59 and retinal ischemia60. Blocking microglia reactivity is known 
69 
 
Manuscript III 
to be neuroprotective in experimental glaucoma61–63. Müller cells and microglia actively 
cross-talk to maintain constant levels of neurotrophic factors important for retinal 
physiology64,65. Microglia can directly trigger the release of several neurotrophic factors 
from Müller cells, including GDNF, LIF, CNTF and NGF17,54,66,67. Furthermore, vimentin 
expression serves as a marker for activated states of microglia18,19,68. In our study, FXN-
overexpressing Müller cells seemed to regulate microglial function under physiological 
conditions, as suggested by reduced vimentin expression in naïve retinae. We propose that 
FXN-mediated modulation of the Müller cell response to lesion impacts microglial 
reactivity, possibly by shifting the microglial activation from a reactive M1-state to a more 
protective M2-state69.  
Taken together, our results show that FXN overexpression in Müller cells improves RGC 
survival after acute ischemia/reperfusion injury and this is associated with an increased 
expression of antioxidant enzymes and neurotrophic factors. Furthermore, our study 
highlights Müller cells as important players in retinal pathologies and indicates that support 
of the glial management of retinal redox homeostasis might constitute a therapeutic 
alternative to overcome neuronal degeneration due to increased oxidative stress. 
  
Materials and Methods 
Animal Guidelines 
All experiments were performed in accordance with the European Convention for Animal 
Care and with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research and were also approved by the local animal care committee (Thüringer 
Landesamt für Verbraucherschutz (TLV) - Abteilung 2 Gesundheitlicher und technischer 
Verbraucherschutz, accreditation numbers: 02-047/08 and 02-013/11). Animals were 
housed in standard cages in groups of 5 animals on a 14-hour light/10-hour dark cycle, with 
food and water available ad libitum, a temperature ranging from 22°C to 25°C and humidity 
ranging from 55% to 60%.  
Male C57BL/6J background and transgenic mice overexpressing FXN, weighing 25 ± 2 g, 
aged 12 ± 1 weeks, were used in the study. Transgenic animals overexpressing FXN in 
Müller cells were generated by breeding homozygous mice carrying cassettes of human 
PVMD2-rtTA and TRE-cre (PVMD2TREcre23,70,71, provided by Dr. Yun-Zheng Le, Department 
of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, USA) to 
heterozygous mice carrying a CMV-driven human FXN cDNA preceded by a loxP-flanked 
70 
 
Manuscript III 
stop cassette (R26CMVFxn/wt, provided by Prof. Michael Ristow, Department of Health 
Sciences and Technology, Swiss Federal Institute of Technology, Zürich, Switzerland), 
hereafter referred to as MGCre-FXN. Cre-mediated excision of the stop cassette leads to 
expression of the FXN gene and of green fluorescent protein (EGFP), as has been shown in 
our previous work with ubiquitous FXN overexpressing mice16, Background mice were 
generated by breeding C57BL/6J with PVMD2TREcre mice, hereafter referred to as MGCre-
B6. Mice were randomized for each experimental setup into a non-lesioned group (MGCre-
B6 n = 22; MGCre-FXN n = 22) or an ischemia group (MGCre-B6 n = 16; MGCre-FXN n = 18).  
Transient Retinal Ischemia  
Transient retinal ischemia (TRI) was performed as previously described16,72. Briefly, mice 
were anesthetized with an intraperitoneal injection of 5% chloral hydrate in phosphate 
buffered saline (PBS; 500 mg/kg body weight; Fluka, Seelze, Germany). After application of 
topical anesthesia (4 mg/ml oxybuprocaine-hydrochloride; Bausch & Lomb GmbH, 
Feldkirchen, Germany), the anterior chamber of the right eye was cannulated with a 30-
gauge needle connected to an elevated normal saline reservoir. Intraocular pressure (IOP) 
was elevated above systolic pressure (increased from 15.5 ± 2.6 mmHg to 93 ± 4.4 mmHg) 
for 45 minutes. IOP was measured using an induction/impact tonometer (TonoLab; Tiolat 
Ltd., Helsinki, Finland). This method has been validated for the mouse eye73. One drop of 
antibiotic solution (ofloxacin; Bausch & Lomb GmbH, Berlin, Germany) was applied topically 
to the treated eye after cannulation. After 45 minutes of ischemia, the needle was 
withdrawn and the IOP normalized. Treated eyes were inspected daily and animals with 
signs of inflammation or iatrogenic cataract were excluded from the study. Animals for RGC 
evaluation were sacrificed with an overdose of chloral hydrate (30%) 14 days after 
ischemia, as previously described16. For microglia analysis, mice were sacrificed 7 days 
after lesion, coinciding with highest microglial proliferation as already reported57. For qRT-
PCR analysis, mice were sacrificed 24 hours post ischemia as described in a previous 
study16. 
Retinal tissue fixation and sectioning 
To localize human FXN (hFXN) expression and evaluate microglia response after ischemic 
injury, retinal sections from background and MGCre-FXN mice were prepared. Briefly, 
animals were sacrificed with an overdose of chloral hydrate (30%), eyes were removed and 
fixed in 4% PFA for 20 min at room temperature (RT), enucleated, again fixed in 4% PFA for 
20 min, washed in PBS and cryoprotected by immersion in 30% sucrose in PBS overnight at 
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4°C. Eyecups were then frozen in an appropriate embedding medium (Tissue Tek; Sakura, 
Loeterwoude, The Netherlands) and cryosectioned into 16 µm slices. 
Retinal whole mounts of MGCre-B6 and MGCre-FXN mice were prepared to evaluate RGC 
survival following ischemia. Eyes were enucleated and retinae were removed and fixed by 
immersion in 4% PFA for 20 min. After washing in PBS, retinae were flattened by making 
incisions from the periphery halfway to the optic nerve to form four symmetric lobes. 
Immunofluorescent staining 
Immunofluorescent staining protocols were similar for retinal slices and whole mounts. 
Retinal sections were dried at 37°C for 45 min and fixed with 4% PFA for 20 min. Retinal 
whole mounts were permeabilized with 0.3% Triton X-100 in PBS for 45 min at RT. Blocking 
was achieved by incubation with 3% bovine serum albumin (BSA) and 10% normal donkey 
serum (NDS) in PBS supplemented with 0.3% Triton X-100 for 2 hours at RT. After non-
specific binding was blocked, whole mounts were incubated with primary antibody raised 
against the RGC-specific transcription factor Brn3a (goat anti-Brn3a, 1:300; Santa Cruz, 
Heidelberg, Germany), whereas slices were incubated with primary antibodies directed 
against ionized calcium-binding adaptor molecule (rabbit anti-Iba1, 1:500; Wako, Neuss, 
Germany), cluster of differentiation 68 (rat anti-CD68, 1:200; Serotec, Düsseldorf, 
Germany), major histocompatibility complex class II (rat anti-MHCII, 1:10,000; affymetrix, 
CA, USA), GFP (goat anti-GFP, 1:100, Acris, Herford, Germany) and glutamine synthetase 
(mouse anti-GLUL, 1:250, Millipore, Darmstadt, Germany) in 5% NDS, overnight at 4°C. 
After washing with PBS, probes were incubated with corresponding secondary antibodies 
(Molecular Probes, Leiden, The Netherlands) in 10% NDS for one hour at RT. For nucleic 
acid staining, the retinal slices were immersed into a DAPI (4'-6-Diamidino-2-phenylindole) 
solution for 5 min. Specificity of the staining was tested by incubation without primary 
antibody. 
Fluorescence microscopy 
RGC survival was evaluated on retinal whole mounts 14 days post-ischemia. Brn3a-labeled 
RGCs were counted in single fields at three different retinal eccentricities in each of the four 
whole mount lobes (1/6, 3/6 and 5/6 from retinal radius; 0.093 mm2 each, 12 fields in 
total) by means of fluorescence microscopy according to Schmeer et al. (2008)74. The 
number of surviving RGCs was expressed as the number of cells per square millimeter and 
cell counts were given as the percentage of corresponding contralateral and non-lesioned 
eyes.  
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The number of GFP+ Müller cells specifically expressing FXN was determined on slices from 
MGCre-FXN mice by counting GLUL+GFP+ cell processes located in the IPL. The results are 
given as percentage from the whole GLUL+ cell population.  
The number of Iba1+ microglia was determined on retinal sections. Cell counts were 
corrected for slice length and expressed as cell count per 1000 µm. The number of reactive 
microglia was assessed by counting Iba1+CD68+ and Iba1+MHCII+ cells.  
Image acquisition and cell counting on retinal slices was performed by confocal laser 
scanning microscopy using the ZEN software (40x magnification, 710 Meta; Carl Zeiss 
Meditec, Jena, Germany). 
Quantitative polymerase chain reaction analysis 
Eyes were enucleated 24 hours post ischemia and retinae were shock frozen in liquid 
nitrogen. Isolation of mRNA was carried out using the QIAzol standard protocol (Qiagen, 
Hilden, Germany). Equal amounts of total retinal mRNA were reversely transcribed into 
cDNA using a Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, Schwerte, 
Germany). qRT-PCR amplification for murine (mFxn) and human FXN (hFXN), antioxidant 
enzymes, growth factors and inflammatory cytokines (primer sequences are depicted in 
Table 1) were carried out with Brilliant II SYBR Green QPCR Mastermix (Agilent 
Technologies, Santa Clara, CA, USA). After denaturing at 95°C for 10 min, 40 amplification 
cycles were carried out as follows: denaturation at 95°C for 60 s, annealing at 60°C for 30 s, 
and elongation at 72°C for 30 s. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) were used as housekeeping genes. 
Relative expression ratios (fold changes) of the target genes were calculated using the Pfaffl 
method75. 
Western blotting 
To evaluate the protein levels of retinal FXN in MGCre-B6 and MGCre-FXN mice, Western 
blotting was performed as previously described16. Primary antibodies raised against FXN 
(1:500; Santa Cruz), β-Actin (1:10,000; abcam, Cambridge, UK) and horseradish peroxidase 
(HRP)-conjugated secondary antibody (1:5000 dilution) were used. Protein bands were 
visualized using an enhanced chemiluminescence reaction kit (Immun-Star WesternC 
Chemiluminescence Kit, BioRad, München, Germany), photographed with Fujifilm LAS-3000 
Imager and analyzed with ImageJ software (1.46v). Measurements were done in duplicate. 
Each band was normalized against the corresponding β-actin band. Changes in protein 
expression were expressed as a percentage of control mice. 
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Statistical Analysis 
All results are expressed as the mean ± standard error of the mean (SEM). Each group 
consisted of at least four animals. Proof of normal distribution was done for all data by a 
Shapiro-Wilk test. For RGC survival analysis, statistical significance was assessed by using 
one-way ANOVA followed by Holm-Sidak post hoc analysis and comparing MGCre-B6 
control mice and treatment groups. For relative gene expression analysis, ratio data were 
log2 transformed and two-way ANOVA followed by Holm-Sidak post hoc analysis was 
applied for comparison of lesion effects between mice strains. For microglia cell counts and 
reactivity marker expression two-way ANOVA followed by Holm-Sidak post hoc analysis was 
applied for comparison of lesion effects between mice strains. For Western blot analysis, 
the results were compared by one-way ANOVA followed by Holm-Sidak post hoc analysis 
comparing background and transgenic mice. SigmaPlot (13.0v) was used and the level of 
significance was set at P < 0.05. 
Data Availability 
The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request. 
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Figure legends 
Figure 1. Expression of the human FXN transcript in the retina from MGCre-FXN mice. (A) 
Relative expression of human FXN (hFXN) mRNA was determined by quantitative 
polymerase chain reaction, normalized against Gapdh and Hprt mRNA levels and depicted 
as fold increase of expression in MGCre-B6 mice. The y-axis is depicted in logarithmic 
scaling. Bars represent the mean ± SEM; n = 6. (B) FXN protein levels of precursor FXN form 
(30 kDa) and mature FXN form (18 kDa) were determined by densitometric analysis of 
Western blotting in MGCre-B6 and MGCre-FXN mice. Values are expressed as a percentage 
of MGCre-B6 mice and normalized against β-actin. Bars represent the mean ± SEM; n = 4. 
(B’) Representative Western blot showing FXN precursor and mature bands for FXN in 
MGCre-B6 and MGCre-FXN mice. Full-length blot is presented in Supplementary Figure 1. 
(C-C’’) GFP expression in MGCre-FXN mice. Immunofluorescent staining of GFP (green), 
which is co-expressed with hFXN protein, and the Müller cell-specific marker glutamine 
synthetase (GLUL, red), as well as DAPI nuclear staining (blue) of retinal sections, were used 
to illustrate the hFXN location in Müller cells. GCL: ganglion cell layer, IPL: inner plexiform 
layer, INL: inner nuclear layer, OPL: outer plexiform layer, ONL: outer nuclear layer. Scale 
bar = 50 μm. 
Figure 2. Effect of FXN overexpression on mRNA levels of the neurotrophic factors Lif, Cntf 
and Bdnf, tumor necrosis factor alpha (Tnfα), catalase (Cat) and vimentin (Vim) in the naïve 
mouse retina. Bars represent the mean ± SEM, dashed lines represent 1.0 ratio, n = 5, two-
way ANOVA. 
Figure 3. Effect of FXN overexpression in Müller cells on RGC survival 14 days after acute 
retinal ischemia/reperfusion. (A) Images of retinal whole-mount preparations from lesioned 
and non-lesioned MGCre-B6 and MGCre-FXN animals at various retinal eccentricities (1/6, 
3/6, 5/6 from retinal radius) are shown. Images were taken with a fluorescence microscope 
(x40). Scale bars = 50 µm. (B) Analysis of RGCs distribution per retinal eccentricity in non-
lesioned MGCre-B6 and MGCre-FXN animals. Numbers of RGCs are expressed as cells/mm², 
n = 4. (B’) Analysis of surviving RGCs after acute retinal ischemia. Numbers of RGCs are 
expressed as percentages from contralateral eyes. Cell counts were determined 14 days 
after the insult. Bars represent the mean ± SEM; n = 4 – 8. *** P < 0.001 vs. MGCre-B6 Ctrl; 
+++ P < 0.001 vs. MGCre-FXN Ctrl. 
Figure 4. Effects of FXN overexpression on IOP and retinal morphology before and after 
acute ischemia/reperfusion. (A) Analysis of retinal layer thickness in naïve mice and after 
acute retinal ischemia. Bars represent the mean ± SEM; n = 5. *** P < 0.001 vs. MGCre-B6 
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Ctrl; +++ P < 0.001 vs. MGCre-FXN Ctrl. (B) IOP measurement before and during increased 
IOP. Bars represent the mean ± SEM; MGCre-B6 n = 16, MGCre-FXN n = 50; Mann-Whitney 
U Rank Sum Test. (C) Representative sections through both control and ischemic retinae 
from MGCre-B6 and MGCre-FXN mice are illustrated. After ischemia, retinal layers, 
particularly the IPL, are severely shrunk. GCL: ganglion cell layer, IPL: inner plexiform layer, 
INL: inner nuclear layer, OPL: outer plexiform layer, ONL: outer nuclear layer. Scale bar = 50 
μm. 
Figure 5. Effect of acute retinal ischemia/reperfusion and FXN overexpression on mRNA 
levels of (A) antioxidant enzymes Gpx1 and Sod1 and (B) neurotrophic factors Cntf and Lif. 
Expression levels of corresponding mRNAs were determined 24 hours after ischemia by 
quantitative polymerase chain reaction and normalized against Gapdh and Hprt. Bars 
represent the mean ± SEM, dashed lines represent 1.0 ratio, n = 5, two-way ANOVA. 
Figure 6. Distribution and localization of reactive microglia in the retina from MGCre-B6 and 
MGCre-FXN mice. Immunofluorescent staining for Iba1 (red), CD68 (cyan) or MHCII (cyan) 
as well as DAPI nuclear staining (blue) in retinal sections. Example sections of MGCre-B6 (A-
C) and MGCre-FXN mice retinae (D-F) before and after lesion are shown. Iba1+ microglia 
(arrowheads) and Iba1+ co-localized with CD68 (notched arrows) or MHCII (circles) were 
observed. GCL: ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, OPL: 
outer plexiform layer, ONL: outer nuclear layer. Scale bar = 50 μm. (A’-C’) and (D’-F’) show 
enlarged squares containing example microglia with different merged channels for MGCre-
B6 and MGCre-FXN mice. From top to bottom: DAPI; DAPI + CD68 or MHCII; DAPI + Iba1; 
Iba1 + CD68 or MHCII. Scale bar = 25 μm. 
Figure 7. Effect of FXN on the expression of microglial reactivity markers. (A) Iba1+ cell 
counts per retinal section (1000 µm in length) in naïve and lesioned MGCre-B6 and MGCre-
FXN mice. Bars represent the mean ± SEM, n = 5, two-way ANOVA. (B) Percentage of CD68 
positive Iba1 cells in naïve and lesioned MGCre-B6 and MGCre-FXN mice. Bars represent 
the mean ± SEM, n = 5, two-way ANOVA. (C) Percentage of MHCII positive Iba1 cells in 
naïve and lesioned MGCre-B6 and MGCre-FXN mice. Bars represent the mean ± SEM, n = 5, 
two-way ANOVA. 
81 
 
Manuscript III 
Tables 
Table 1: RGC quantification in murine retinal whole mount preparations as a function of the retinal radius 
 
Treatment Control TRI 
retinal radius 1/6 3/6 5/6 1/6 3/6 5/6 
   
mice strain  MGCre-B6  
 
RGC survival       
cells/mm² 3275 ± 166 2912 ± 180 1975 ± 41 904 ± 99 891 ± 36 1063 ± 58 
Percentage vs. 
contralateral 
eye 
104 ± 11% 98 ± 13% 116 ± 9% 25 ± 3% 29 ± 1% 63 ± 5% 
Mean ± SEM 106 ± 11% 35 ± 2% 
n=  4   6  
       
mice strain  MGCre-FXN  
 
RGC survival       
cells/mm² 3258 ± 339 2974 ± 207 2103 ± 139 1358 ± 109*  1416 ± 159* 1098 ± 192 
Percentage vs. 
contralateral 
eye 
96 ± 10% 104 ± 11% 105 ± 12% 54 ± 9%* 54 ± 11%* 60 ± 9% 
Mean ± SEM 102 ± 10% 58 ± 6% * 
n= 4 8 
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Table 2: Primer sequences for mRNAs analyzed in the study, together with the expected product length. 
 
Gene name   Primer Seq. (5'->3') Prod. size (bp) 
hFXN Fw CCTTGCAGACAAGCCATACA 
150 
human Fratxin Rev CCACTGGATGGAGAAGATAG 
Fxn Fw CCTGGCCGAGTTCTTTGAAG 
152 
mouse FXN Rev GCCAGATTTGCTTGTTTGG 
Antioxidant response    
Gpx1 Fw GGGACTACACCGAGATGAACGA 
197 
glutathione peroxidase 1 Rev ACCATTCACTTCGCACTTCTCA 
Sod1 Fw GTCCGTCGGCTTCTCGTCT 
163 
superoxide dismutase [Cu-Zn] Rev CACAACTGGTTCACCGCTTG 
Sod2 Fw ATTAACGCGCAGATCATGCA 
161 
superoxide dismutase [Mn] Rev TGTCCCCCACCATTGAACTT 
Cat  Fw GCAGATACCTGTGAACTGTC 
229 
catalase Rev GTAGAATGTCCGCACCTGAG 
Hmox1 Fw GGTGATGGCTTCCTTGTACC 
155 
heme oxygenase 1 Rev AGTGAGGCCCATACCAGAAG 
Glial response    
Vim Fw TGAAGGAAGAGATGGCTCGT 194 
Vimentin Rev GGTGTCAACCAGAGGAAGTGA 
Gfap Fw AGAAAGGTTGAATCGCTGGA 
176 
glial fibrillary acidic protein Rev GCCACTGCCTCGTATTGAGT 
Glast Fw GCCCTCCGACCGTATAAAAT 
128 
Glutamate aspartate transporter Rev GCCATTCCTGTGACGAGACT 
Glul Fw ATCGGGTGTGCGAAGACTTT 181 
glutamine synthetase Rev CGAATGTGGTACTGGTGCCT 
Neurotrophic factors    
Lif Fw AATGCCACCTGTGCCATACG 
216 
leukemia inhibitory factor Rev CAACTTGGTCTTCTCTGTCCCG 
Ngf Fw AGCATTCCCTTGACACAG 
99 
nerve growth factor Rev GGTCTACAGTGATGTTGC 
Bdnf Fw TGGCTGACACTTTTGACCAC 
131 
brain-derived neurotrophic factor Rev CAAAGGCACTTGACTGCTGA 
Cntf Fw ATGACTGAGGCAGAGCGACT 
157 
ciliary neurotrophic factor Rev AGGCAGAAACTTGGAGCGTA 
Gdnf Fw TGGGCTATGAAACCAAGGAG 
142 
glial cell line-derived neurotrophic factor Rev CAACATGCCTGGCCTACTTT 
Inflammatory markers    
Tnf-alpha Fw GTCTACTGAACTTCGGGGTGAT 
102 
Tumor necrosis factor alpha Rev ATGATCTGAGTGTGAGGGTCTG 
Il1b Fw GAAGAGCCCATCCTCTGTGA 
96 
Interleukin 1 beta Rev TTCATCTCGGAGCCTGTAGTG 
                83 
 
Manuscript III 
Housekeeping genes    
Hprt Fw TGACACTGGTAAAACAATGCA 
94 hypoxanthine-guanine 
phosphoribosyltransferase Rev GGTCCTTTTCACCAGCAAGCT 
Gapdh Fw AGGTCGGTGTGAACGGATTTG 
123 
Glyceraldehyde 3-phosphate dehydrogenase Rev TGTAGACCATGTAGTTGAGGTCA 
fw, forward primer; rev, reverse primer 
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5 Closing discussion 
Most retinal pathologies, including diabetic retinopathy, macular degeneration, retinal 
detachment, glaucoma and ischemia, result in the activation of Müller cells, the most 
abundant retinal glial cell type (Bringmann et al. 2009). The disease or lesion-induced 
response of Müller cells includes the buffering of elevated potassium levels and uptake of 
excess glutamate, which would otherwise be neurotoxic (Lucas and Newhouse 1957; 
Napper et al. 1999; Bringmann et al. 2009). Moreover, Müller cells release neurotrophic 
factors, growth factors, and cytokines to protect photoreceptors and neurons from cell 
death (Harada et al. 2000; Fontaine et al. 2002; Fu et al. 2015; Garcia et al. 2014). 
Conversely, Müller cell activation can also have detrimental effects, for instance by VEGF-
induced leakage and neovascularization (Croll et al. 2004; Yasuhara et al. 2004; Kilic et al. 
2006; Pierce et al. 1995; Tolentino et al. 2002) or impaired neuronal recovery and axonal 
regrowth by glial-secreted extracellular matrix substrates (Shen et al. 2008; Moreau-
Fauvarque et al. 2003). Moreover, Müller cells mediate cytotoxicity by the release of 
soluble factors such as the proinflammatory cytokine TNF-α which activates TNF-R1 and 
triggers apoptosis (Cotinet et al. 1997; Tezel et al. 2001).  
The precise timing for the transition between the supportive and detrimental responses of 
Müller cells to lesion, as well as the underlying mechanisms is poorly understood. The 
critical role of Müller glia in regulating neuronal homeostasis, but also their transition to a 
detrimental gliotic response after injury or in disease, converts them to a potential 
therapeutic target for the treatment of neurodegenerative retinal diseases.  
This study aimed to determine whether modulation of the Müller cell gliotic response after 
injury constitutes a feasible target to reduce neuronal damage after an ischemic injury to 
the retina by answering two questions: i) what is the time course for the development of 
the Müller cells neuroprotective and detrimental responses after an acute ischemic injury, 
and ii) what is the effect of selective FXN overexpression, and its associated antioxidative 
activity in Müller cells on neuronal survival after ischemia.  
 The development of neuroprotective and detrimental responses of 5.1
Müller cells after lesion is time-dependent 
Worldwide, glial cells are currently the focus of research in many labs, and increasing 
evidence supports their critical role in brain function during health and disease. Approaches 
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to modulate glial activity and to reduce neuronal damage after injury have recently been 
evaluated. In particular, several studies have focused on the regulation of the gliotic activity 
of Müller cells. For instance, inhibition of reactive gliosis, by intravitreal injection of the glial 
toxin neurostatin, prevents kainic acid-induced apoptotic death of retinal neurons and 
provides substantial neuroprotection (Ganesh and Chintala 2011). Inhibition of 
intermediate filament polymerization with withaferin A, a blocker of type III intermediate 
filament dynamics, prevented a p38 MAPK-dependent secretion of TNF-α, resulting in 
reduced Müller cell gliosis and neuronal apoptosis (Livne-Bar et al. 2016). FC has also been 
used to inhibit glial cells and to study the impact of glial metabolic impairment on neuronal 
cells in vitro and in vivo. In contrast to the aforementioned studies, FC-mediated inhibition 
of glial cells was detrimental for neurons. Inhibition of astrocytic mitochondria with 0.25 
mM FC, prior to glutamate treatment, increased the vulnerability of co-cultured neurons to 
glutamate toxicity (Voloboueva et al. 2007). In addition, inhibition of glial cell activity with 
1.0 mM FC, 10 minutes before middle cerebral artery occlusion (MCAO), caused significant 
cell damage in rats (Hosoi et al. 2006). These findings demonstrated that inhibition of glial 
metabolism increases neuronal vulnerability to a short-term transient ischemia. FC 
administered after MCAO not only inhibited reactive astrocytes, but also suppressed 
neurovascular markers and worsened the neurological outcome (Hayakawa et al. 2010; 
Hayakawa et al. 2009). In this study, FC was given once every 2 days starting 5 days after 
ischemia which showed that inhibition of glial cells at late reperfusion also increases 
neuronal susceptibility to ischemia. 
In addition to the aforementioned studies, the impact of glial cell inhibition after lesion has 
been previously evaluated, for instance, by the post-conditioning paradigm. In the retina, 
post-conditioning has been induced by re-increasing the IOP immediately or as late as 24 
hours after ischemia (Dreixler et al. 2010; Fernandez et al. 2009a). Both immediate and 
delayed post-conditioning were found to reduce glial cell reactivity concomitant with a 
robust functional recovery and increased survival of RGCs after ischemia (Fernandez et al. 
2009a; Schallner et al. 2012; Fernandez et al. 2009b; Dreixler et al. 2011). These findings 
argue against a specific timing for the transition from neuroprotective to detrimental 
gliosis. However, post-conditioning is not a cell-specific mechanism and affects both the 
glial- and neuronal response to ischemia.  
The question on the effect of a specific down-regulation of the gliotic Müller cell response 
on neuronal survival in the acute and sub-chronic phase after lesion remained unanswered. 
Addressing this question is highly relevant to determine a putative time window for 
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therapeutic interventions aimed at reducing neuronal damage after lesion. In this study, in 
order to evaluate the time-course for the development of neuroprotective and detrimental 
responses in Müller cells, the cellular metabolism was transiently inhibited with FC, as 
previously described (Virgili et al. 1991). This was done at different time points before and 
during the reperfusion phase after ischemia. In agreement with previous findings 
(Voloboueva et al. 2007; Hosoi et al. 2006), a transient metabolic inhibition in Müller cells 
at lesion onset was not neuroprotective, but rather increased neuronal cell death. 
Therefore, the gliotic response of Müller cells during and early after ischemia supports 
neuronal survival. In fact, metabolic inhibition did not affect RGCs survival for up to 10 
hours after ischemia. During this time, Müller cells seem not to influence the degeneration 
of RGCs. However, Müller cell inhibition starting 12-18 after lesion leads to increased 
neuronal survival. Hence, the Müller cell response to lesion seems to become detrimental 
during this time frame. 
In conclusion, the Müller cell gliotic response is neuroprotective at the onset of a retinal 
ischemia/reperfusion injury, but progresses to a more detrimental response 12 to 18 hours 
after reperfusion onset. This transition can be modulated using a specific glial metabolic 
inhibitor. Findings indicate a time window of at least 6 hours starting 12 hours after 
reperfusion which would allow for therapeutic interventions aimed to reduce detrimental 
gliotic effects and improve neuronal survival after an acute ischemic injury. Future studies 
will determine whether these positive effects are long-lasting or only of short duration. 
 Frataxin overexpression improves the intrinsic antioxidative capacity 5.2
in the retina 
One hallmark of retinal ischemia/reperfusion injury is the generation of excessive ROS 
during reperfusion. Glial cells react to increased oxidative stress by releasing anti-oxidative 
factors (Schütte and Werner 1998; Bringmann and Reichenbach 2001; García and Vecino 
2003; Bringmann et al. 2006). In this study, protocols to enhance the anti-oxidative 
response in the retina and, specifically in Müller cells, were established in order to improve 
the glial neuroprotective activity and to reduce detrimental effects of the gliotic response 
during and after lesion. This was achieved by generating transgenic mice overexpressing a 
copy of the human mitochondrial enzyme FXN ubiquitously in the retina or specifically in 
retinal Müller cells. We hypothesized that FXN overexpression would reduce oxidative 
stress after ischemia resulting in increased neuronal survival. Results show that an 
increased expression of the endogenous mouse FXN is part of the intrinsic retinal response 
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to ischemia. FXN overexpression in transgenic mice resulted in improved neuronal survival. 
Furthermore, ubiquitous overexpression of human FXN resulted in elevated levels of 
enzymes involved in oxidative stress response, namely glutathione peroxidase 1 (Gpx1), 
superoxide dismutase 2 (Sod2) and catalase, all of which are well known for their anti-
oxidative properties. Importantly, mRNA expression levels of heme oxygenase-1 (Hmox1) 
and hypoxia inducible factor 2 alpha (Hif2α), were also increased after ischemia in FXN 
overexpressing mice compared to non-transgenic controls. Both factors are known to be 
selectively expressed by Müller cells (Arai-Gaun et al. 2004; Mowat et al. 2010). This finding 
indicated that Müller cells might play a critical role in the FXN-mediated neuroprotective 
response following ischemia. To test for the role of Müller cells in the FXN-mediated 
response to ischemia and the feasibility to selectively modulate their activity towards a 
more neuroprotective phenotype, a second mouse model which specifically overexpresses 
FXN in Müller cells was generated. FXN overexpression increased RGC survival to a similar 
extent as in mice ubiquitously overexpressing FXN in the retina. Also in this paradigm, anti-
oxidant enzymes were significantly involved in the response to the ischemic lesion. In 
particular, Gpx1 was significantly increased to the same extent in both FXN overexpressing 
mice strains after lesion. Findings from this study are in agreement with previous studies 
showing that FXN overexpression in murine 3T3L1 cells activates glutathione peroxidase 
and increases levels of thiols, thereby exerting anti-oxidative effects (Shoichet et al. 2002). 
In addition, FXN overexpression in transgenic flies, renders them resistant to toxicity 
induced by iron, paraquat, and hydrogen peroxide, suggesting that FXN may protect cells 
against oxidative stress (Runko et al. 2008). Furthermore, delivery of the fusion proteins 
Tat-FXN and PEP-1-FXN suppressed neuronal cell death in a transient forebrain ischemia 
model. PEP-1-FXN enhanced cell proliferation and neuroblast differentiation by reducing 
lipid peroxidation and Tat-FXN upregulated the expression of superoxide dismutase and 
consequently inhibited the generation of 4-hydroxynonenal, which is produced by lipid 
peroxidation (Kim et al. 2010; Kim et al. 2011).  
It is important to note that for our study we used a constitutive and a conditional mouse 
model overexpressing FXN. In both of these models FXN was already overexpressed prior to 
the lesion. In the constitutive mouse model (Deleter mouse), Cre-recombinase was 
expressed under the transcriptional control of a human cytomegalovirus minimal promoter 
in all tissues (Schwenk et al. 1995). Expression of Cre-recombinase in Müller cells was 
controlled by the promoter of the human vitelliform macular dystrophy (VMD)-2 (Ueki et al. 
2009; Zhu et al. 2010; Zhou et al. 2014). This mouse model was the only available model for 
a Müller cell-specific Cre expression; however, the VMD-2-promoter is only active in Müller 
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cells during early embryonic development (Zhu et al. 2010). Hence, overexpression of FXN 
was induced starting as early as embryonic day 15. This means that for both transgenic 
approaches, FXN was already overexpressed during retinal development. Interestingly, FXN 
overexpression during development has been described to have deleterious effects in 
Drosophila (Navarro et al. 2011), but not in mice (Miranda et al. 2004; Schulz et al. 2010). 
Although no obvious alterations were found in other mouse strains overexpressing FXN, an 
increased number of damaged lenses comparable to those found in animals with cataract 
(Varma et al. 1984) was noticed in this study. Hence, these mice were excluded from the 
studies. In addition, partially altered retinal structures with expanded retinal layers 
including GCL/IPL and INL, which were thickened by approximately 20%, were observed. 
Furthermore, changes in mRNA expression levels for Tnfα, Bdnf, Cntf, Lif, catalase and 
vimentin, and slight, but significant higher IOP were found in naïve transgenic mice 
compared to non-transgenic mice. Different IOP levels ranging from 11.1 ± 0.5 mmHg to 
19.3 ± 0.3 mmHg have been described in different mouse strains (Savinova et al. 2001). 
However, these different IOPs did not result in morphological changes or development of 
glaucoma. Nevertheless, it cannot be ruled out that early additional copies of FXN might 
influence retinal development and Müller cell functions before lesion, resulting in an 
induction of long-lasting retinal ischemic tolerance. This is comparable to preconditioning, 
which is also neuroprotective and has been shown to occur after treatment with the iron 
chelator deferroxamine (Zhu et al. 2008). Whether a post-lesion-induced increase of FXN 
would lead to a similar neuroprotective effect after an ischemic injury remains an open 
question. 
In conclusion, FXN overexpression improves the intrinsic response to oxidative stress which 
results in increased neuronal survival. This supports the notion that improving the Müller 
cell response to oxidative stress during retinal ischemia is a feasible approach to achieve 
neuroprotection and to overcome detrimental gliotic effects. In addition, results indicate 
that in spite of improved neuronal survival after injury, genetic interventions like the one 
described in this study might also have unpredictable side effects with undefined 
morphological and functional consequences, which have to be carefully evaluated.  
 Signaling pathways involved in cell death and neuroprotection in this 5.3
study 
At present there are no effective treatments for most retinal degenerative diseases; 
however, a variety of potential approaches are being evaluated including preventive 
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strategies that aim to counteract the underlying disease mechanisms (e.g. pharmacological 
or genetic interventions to alter specific cellular pathways and genes). Other strategies 
focus on cell death prevention by treatment with neurotrophic factors, or cell replacement 
therapies by transplantation. Development of effective therapeutic treatments for 
neurodegenerative diseases requires analysis of temporal changes in the cellular responses 
with the affected gene networks and signaling pathways.  
Importantly, retinal neurons are not compromised simultaneously, but die at different rates 
after ischemia. Cell death can be executed by at least two well-established mechanisms, 
necrosis and apoptosis. Necrosis starts within the first four hours after acute retinal 
ischemia but is rarely detectable after 1 day of reperfusion (Joo et al. 1999). Apoptosis of 
neuronal cells starts 6 to 12 hours after ischemia and peaks at 24 hours of reperfusion 
(Katai and Yoshimura 1999). In addition, cell death can occur following an alternative 
programmed mechanism, known as necroptosis (Rosenbaum et al. 2010; Dvoriantchikova 
et al. 2014). Necroptosis seems to take place within the first 12 to 24 hours after injury 
(Gao et al. 2014). In addition to these two waves of neuronal cell death, our study provides 
evidence that also the gliotic response after retinal ischemia is comprised of two main time-
dependent components, a first early neuroprotective phase followed by a late detrimental 
second phase. However, our results support the notion that cells dying by necrosis 
immediately after lesion cannot be effectively rescued. In contrast, cells dying by apoptosis 
or necroptosis can be rescued by means of different approaches (Chinskey et al. 2014)., 
including those described in this study. 
During lesion and reperfusion onset, Müller cells seem to be very important for neuronal 
survival. In this initial phase, differentially expressed genes are related to changes in 
metabolism (Andreeva et al. 2014). Several studies show that metabolic support via 
injecting dextrose or glucose into the eye vitreous during ischemia is neuroprotective (Büchi 
et al. 1991; Romano et al. 1993; Romano et al. 1998; Casson et al. 2004). In support of this, 
we show that reduced Müller cell activity during this phase impairs RGCs survival after 
lesion. Delivery of neurotrophic factors during or immediately after injury also sustains 
ganglion cell survival (Wong et al. 2014). Importantly, targeting the sub-chronic phase after 
ischemic injury, which is characterized by enhanced inflammatory and immune responses 
as well as highly regulated cell death related genes (Andreeva et al. 2014; Produit-
Zengaffinen et al. 2009) is also effective in neuroprotection and clinically relevant. Delayed 
administration of neurotrophic factors in retinal injury was shown to improve neuronal 
survival (Kyhn et al. 2009; Lambiase et al. 2009; Xiao and Zhang 2010; Checa-Casalengua et 
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al. 2011; Yang et al. 2011; Colafrancesco et al. 2011). In agreement with this, inhibition of 
Müller cell response to ischemia by FC increased and prolonged expression of endogenous 
neurotrophic factors including Bdnf, Gdnf and Ngf. In general, NGF and BDNF control 
neuronal survival via two types of receptors: the tropomyosin receptor kinase (Trk) family 
of high-affinity tyrosine kinase receptors which is associated with neuronal survival, and the 
low-affinity p75NTR receptor which is implicated in neuronal apoptosis and mainly expressed 
in Müller cells. In addition, the GDNF receptors GFRα1 and RET have also been localized to 
Müller cells (reviewed by Kimura et al. 2016; Bringmann et al. 2009). One might speculate 
that the diminished metabolism of Müller cells after FC treatment leads to an altered 
response of these cells to neurotrophic factors, thereby influencing neurotrophic factor 
expression. In support of this, GDNF positively regulates its own expression, leading to a 
long-lasting activation of the GDNF signaling pathway in neuronal cell cultures (He and Ron 
2006), whereas a microRNA-BDNF negative feedback signaling loop has been described in 
the brain (Keifer et al. 2015). An autocrine loop involving TNF-α contributes to the 
production of NGF and GDNF in astrocytes (Kuno et al. 2006). Interestingly TNF-α is 
increased in FC treated mice. Therefore, inhibition of Müller cells might directly lead to a 
prolonged neuron-supportive signaling of these neurotrophic factors. However, further 
research is needed to support this notion. Interestingly, supporting Müller cells by FXN 
overexpression also leads to increased expression of neurotrophic factors. In particular 
Cntf, which is typically expressed by Müller cells, is higher expressed (Ji et al. 2004; Honjo et 
al. 2000). This evidence argues for the involvement of a different neuroprotective pathway 
in this Müller cell response compared to FC treated Müller cells. Nevertheless, all of these 
factors are well described for reducing cellular apoptosis and the expression of cell death 
related genes (Kimura et al. 2016).  
The two approaches evaluated in this study led to increased expression of antioxidant 
enzymes. Oxidative stress is, as previously mentioned, one of the main triggers for RGC 
death in retinal ischemia/reperfusion injury (Osborne et al. 2004; Williams 2008) and 
therefore, enhanced antioxidant enzyme expression directly correlates with increased 
neuronal survival observed here (Arai-Gaun et al. 2004; Liu et al. 2012b). Furthermore, 
oxidative stress is linked to inflammation in glaucoma (Tezel 2006; Pinazo-Durán et al. 
2013). Importantly, microglia reactivity was decreased in FXN mice. Reduced microglia 
reactivity might result from a better antioxidant capacity of the Müller cells and improved 
function of these cells. The possible mechanism linking increased Müller cell function and 
decreased microglia reactivity will be addressed in future studies.  
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In conclusion, it was shown that the transition from a neuroprotective to detrimental gliotic 
response in Müller cells seems to be timed with changes in the inflammatory and immune 
responses as well as the regulation of cell death related genes. Impairing the Müller cell 
metabolism during this transition helped to reduce detrimental effects by increasing and 
prolonging the expression of endogenous neurotrophic factors and antioxidant enzymes. 
Support of Müller cells by increasing their oxidative stress response was also associated 
with increased levels of neuroprotective factors and decreased microglial reactivity. 
However, the sources of the neuroprotective or regulatory factors are not known. Some 
factors are produced by Müller cells, but further studies are required to identify the cell 
types responsible for the increased expression of these factors. 
 Combined neuroprotective strategies: alternatives to improve 5.4
neuronal survival after lesions?  
One interesting observation in this study was the fact that, independently of the approach 
used (FC or FXN) the degree of survival of the neuronal cell population did not increase over 
60-70% (figure 2). Similar survival rates were also described by other researchers using the 
same lesion model. Zhu et al. (2002) obtained a survival rate of 65% after preconditioning. 
Delivery of Nec1, an inhibitor of necroptosis, one hour prior to an ischemic injury, rescued 
66% of RGCs (Dvoriantchikova et al. 2014). Ueda et al. (2004) delivered nefiracetam, which 
activates voltage-dependent N-type and L-type calcium channels, 30 min before or 24 hours 
after lesion onset and also obtained a neuronal survival rate of 65%. Hence, different 
approaches for neuroprotection lead to similar levels of neuronal survival after acute retinal 
ischemia. These findings point to a limit in the number of cells that can be saved following a 
retinal insult, independently of the strategy used. One possible reason for this is that some 
cells are damaged beyond recovery and cannot be rescued, as already discussed. Another 
reason might be that most approaches rely on the use of pharmacological and genetic 
strategies which target one specific pathway in a single cell population, mostly neuronal. 
It is conceivable that this apparent limit might be overcome by using a combined approach 
targeting one or more mechanisms in multiple cell types. Such an approach has already 
been evaluated for focal cerebral ischemia by combining the positive effects of therapeutic 
hypothermia with drugs interrupting one or more events of the ischemic cascade (reviewed 
by Goossens and Hachimi-Idrissi, 2014). The use of combined therapies might also serve to 
extend the time window for further delivery of additional neuroprotective agents (Qian et 
al. 2016; Aronowski et al. 1996; Fu et al. 2009). 
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In order to test this concept, we used a combined approach and delivered FC into FXN 
overexpressing mice. It was expected that this combination would further increase the 
neuronal survival after acute ischemia. However, this combined approach did not result in a 
higher level of RGCs survival (figure 2). It is possible that these two effects do no act 
synergistically. This is in agreement with other studies using a combination of pre- and post-
conditioning, which also did not result in improved neuronal survival compared to either 
pre- or post-conditioning anlone (Dreixler et al. 2010). 
As already mentioned, most studies focus mainly on neuronal mechanisms of injury. 
Recently, a new focus has been set on brain astrocytes i.e. for the treatment of stroke 
(Barreto et al. 2011; Liu and Chopp 2016). In our study, the therapeutic value of targeting 
Müller cells for the treatment of retinal ischemia was assessed. We show that selective 
modulation of the function of Müller cells was sufficient to achieve significant 
neuroprotection after retinal ischemia. In addition, we found that this strategy also led to 
significant changes in another non-neuronal cell type, the microglia. It is well known that 
besides gliotic alterations of Müller cells, microglia cells also become reactive in glaucoma 
(Inman and Horner 2007; Bosco et al. 2011; McKinnon et al. 2009). Furthermore, a negative 
 
Figure 2: Exemplary graph for the analysis of surviving RGCs 7 to 14 days after acute retinal 
ischemia/reperfusion injury in mice eye. Numbers of RGCs are expressed as percentages from contralateral non-
ischemic eyes. Cell counts were determined 7 days after ischemia in retinae treated with FC and 14 days post 
lesion in ubiquitous FXN overexpressing (Deleter FXN) and Müller cells-specific FXN overexpressing mice (Vmd2-
cre-FXN). Bars represent the mean ± SEM, dashed line represents 100 % of the naïve control eyes.  
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association between the number of surviving RGCs and the extent of microgliosis has 
already been described (Liu et al. 2012a). In the study presented here, decreased microglia 
reactivity was observed after FXN overexpression. Additionally, also in an MCAO model, 
microglia are most likely the key player for a worse neurological outcome after late FC 
administration (Hayakawa et al. 2010; Hayakawa et al. 2009). Müller glia and microglia 
communicate in a bi-directional manner by influencing the secretion of neurotrophic and 
inflammatory factors (Wang et al. 2011). Furthermore, microglia can also interact with 
neurons by secreting growth factors (Vecino et al. 2016) and vice versa. Glia cells are 
affected by factors secreted from healthy or damaged neurons including fractalkine, which 
suppresses microglia (Cardona et al. 2006), or glutamate, which activates glia cells. These 
findings, which highlight critical interactions between different cell types, strongly support 
the putative therapeutic value of a combined strategy aimed to target multiple cell 
populations to increase neuronal survival after lesion or during disease. This issue deserves 
further research. Morover, later time points after ischemia and FC treatment should be 
evaluated to clarifiy whether the observed surviving RGCs are only stalled in their 
progression to neuronal death or whether it represents a true protection. In addition, it 
would be worthwhile to investigate the effect of the manipulation of Müller cells in slow 
retinal degenerative disease models such as glaucoma or diabetic retinopathy.   
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